U.S. patent number RE45,763 [Application Number 14/035,420] was granted by the patent office on 2015-10-20 for antibodies to troponin i and methods of use thereof.
This patent grant is currently assigned to Abbott Laboratories. The grantee listed for this patent is Susan E. Brophy, Dagang Huang, Bailin Tu, Lowell J. Tyner, Robert N. Ziemann. Invention is credited to Susan E. Brophy, Dagang Huang, Bailin Tu, Joan D. Tyner, Robert N. Ziemann.
United States Patent |
RE45,763 |
Brophy , et al. |
October 20, 2015 |
Antibodies to troponin I and methods of use thereof
Abstract
The subject invention relates to antibodies to troponin I as
well as methods of use thereof. In particular, such antibodies may
be used to detect Troponin I in a patient and may also be used in
the diagnosis of, for example, a myocardial infarction or acute
coronary syndrome.
Inventors: |
Brophy; Susan E. (Grayslake,
IL), Tu; Bailin (Libertyville, IL), Huang; Dagang
(Mundelein, IL), Tyner; Joan D. (N/A), Ziemann; Robert
N. (Palatine, IL) |
Applicant: |
Name |
City |
State |
Country |
Type |
Brophy; Susan E.
Tu; Bailin
Huang; Dagang
Tyner; Lowell J.
Ziemann; Robert N. |
Grayslake
Libertyville
Mundelein
Chicago
Palatine |
IL
IL
IL
IL
IL |
US
US
US
US
US |
|
|
Assignee: |
Abbott Laboratories (Abbott
Park, IL)
|
Family
ID: |
42102721 |
Appl.
No.: |
14/035,420 |
Filed: |
September 24, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
Reissue of: |
12391937 |
Feb 24, 2009 |
8030026 |
Oct 4, 2011 |
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K
16/18 (20130101); C07K 14/4716 (20130101); A61P
9/10 (20180101); C07K 2317/565 (20130101); C07K
2317/24 (20130101); C07K 2317/92 (20130101); C07K
2317/622 (20130101) |
Current International
Class: |
C12P
21/04 (20060101); C12P 21/06 (20060101); C12N
5/00 (20060101); C12N 5/07 (20100101); C07H
21/04 (20060101); C07K 16/18 (20060101); C07K
14/47 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
86631 |
|
Aug 1983 |
|
EP |
|
229246 |
|
Jul 1987 |
|
EP |
|
0229246 |
|
Jul 1987 |
|
EP |
|
239400 |
|
Sep 1987 |
|
EP |
|
0239400 |
|
Sep 1987 |
|
EP |
|
519596 |
|
Dec 1992 |
|
EP |
|
0519596 |
|
Dec 1992 |
|
EP |
|
592106 |
|
Jul 1993 |
|
EP |
|
239400 |
|
Mar 1994 |
|
EP |
|
592106 |
|
Apr 1994 |
|
EP |
|
0592106 |
|
Apr 1994 |
|
EP |
|
0239400 |
|
Aug 1994 |
|
EP |
|
1176195 |
|
Jan 2002 |
|
EP |
|
1176195 |
|
Jan 2002 |
|
EP |
|
519596 |
|
Feb 2005 |
|
EP |
|
0519596 |
|
Feb 2005 |
|
EP |
|
2014302 |
|
Jan 2009 |
|
EP |
|
2779526 |
|
Dec 1999 |
|
FR |
|
8901334 |
|
May 1990 |
|
GB |
|
9101134 |
|
Jan 1992 |
|
GB |
|
9201755 |
|
Apr 1993 |
|
GB |
|
9005144 |
|
May 1990 |
|
WO |
|
9005144 |
|
May 1990 |
|
WO |
|
9005370 |
|
May 1990 |
|
WO |
|
9001443 |
|
Nov 1990 |
|
WO |
|
9014424 |
|
Nov 1990 |
|
WO |
|
9014424 |
|
Nov 1990 |
|
WO |
|
9014430 |
|
Nov 1990 |
|
WO |
|
9014430 |
|
Nov 1990 |
|
WO |
|
9014443 |
|
Nov 1990 |
|
WO |
|
9105548 |
|
May 1991 |
|
WO |
|
9105548 |
|
May 1991 |
|
WO |
|
9105939 |
|
May 1991 |
|
WO |
|
9105939 |
|
May 1991 |
|
WO |
|
9109630 |
|
Jul 1991 |
|
WO |
|
9109630 |
|
Jul 1991 |
|
WO |
|
9109967 |
|
Jul 1991 |
|
WO |
|
9109967 |
|
Jul 1991 |
|
WO |
|
9117271 |
|
Nov 1991 |
|
WO |
|
9117271 |
|
Nov 1991 |
|
WO |
|
9201047 |
|
Jan 1992 |
|
WO |
|
9201047 |
|
Jan 1992 |
|
WO |
|
9209690 |
|
Jun 1992 |
|
WO |
|
9209690 |
|
Jun 1992 |
|
WO |
|
9215679 |
|
Sep 1992 |
|
WO |
|
9215679 |
|
Sep 1992 |
|
WO |
|
9218619 |
|
Oct 1992 |
|
WO |
|
9218619 |
|
Oct 1992 |
|
WO |
|
9219244 |
|
Nov 1992 |
|
WO |
|
9219244 |
|
Nov 1992 |
|
WO |
|
9220791 |
|
Nov 1992 |
|
WO |
|
9220791 |
|
Nov 1992 |
|
WO |
|
9301288 |
|
Jan 1993 |
|
WO |
|
9301288 |
|
Jan 1993 |
|
WO |
|
9306213 |
|
Apr 1993 |
|
WO |
|
9401234 |
|
Jan 1994 |
|
WO |
|
9401234 |
|
Jan 1994 |
|
WO |
|
9601878 |
|
Jun 1996 |
|
WO |
|
9618978 |
|
Jun 1996 |
|
WO |
|
9620698 |
|
Jul 1996 |
|
WO |
|
9620698 |
|
Jul 1996 |
|
WO |
|
9729131 |
|
Aug 1997 |
|
WO |
|
9729131 |
|
Aug 1997 |
|
WO |
|
9732572 |
|
Sep 1997 |
|
WO |
|
9732572 |
|
Sep 1997 |
|
WO |
|
9744013 |
|
Nov 1997 |
|
WO |
|
9744013 |
|
Nov 1997 |
|
WO |
|
9816280 |
|
Apr 1998 |
|
WO |
|
9831346 |
|
Jul 1998 |
|
WO |
|
9831346 |
|
Jul 1998 |
|
WO |
|
9915154 |
|
Apr 1999 |
|
WO |
|
9915154 |
|
Apr 1999 |
|
WO |
|
9920253 |
|
Apr 1999 |
|
WO |
|
9920253 |
|
Apr 1999 |
|
WO |
|
9954342 |
|
Oct 1999 |
|
WO |
|
9954342 |
|
Oct 1999 |
|
WO |
|
9966903 |
|
Dec 1999 |
|
WO |
|
9966903 |
|
Dec 1999 |
|
WO |
|
0183525 |
|
Nov 2001 |
|
WO |
|
0183525 |
|
Nov 2001 |
|
WO |
|
02072636 |
|
Sep 2002 |
|
WO |
|
02072636 |
|
Sep 2002 |
|
WO |
|
03016466 |
|
Feb 2003 |
|
WO |
|
03016466 |
|
Feb 2003 |
|
WO |
|
03035835 |
|
May 2003 |
|
WO |
|
03035835 |
|
May 2003 |
|
WO |
|
2005000901 |
|
Jan 2005 |
|
WO |
|
WO2005000901 |
|
Jan 2005 |
|
WO |
|
2005100584 |
|
Oct 2005 |
|
WO |
|
2005100584 |
|
Oct 2005 |
|
WO |
|
Other References
Eriksson et al. (2005) "Comparison of Cardiac Troponin I
Immunoassays Variably Affected by Circulating Autoantibodies,"
Clin. Chem. 51(5):848-855. cited by applicant .
Hytest 1999 Product Catalog. cited by applicant .
Hytest 2000 General Product Catalog. cited by applicant .
Hytest 2001 Cardiac Markers Panel. cited by applicant .
Hytest 2001-2002 General Product Catalog. cited by applicant .
Hytest 2003 General Product Catalog. cited by applicant .
Hytest 2004 Cardiac Markers Panel. cited by applicant .
Hytest 2004-2005 General Product Catalog. cited by applicant .
Hytest 2005 Markers of Cardiovascular Diseases Catalog. cited by
applicant .
Hytest 2005-2006 General Product Catalog. cited by applicant .
Hytest 2006-2007 General Product Catalog. cited by applicant .
Hytest 2007 Markers of Cardiovascular Diseases Catalog. cited by
applicant .
Hytest 2007-2008 General Product Catalog. cited by applicant .
Hytest 2008-2009 General Product Catalog. cited by applicant .
Katrukha (2006) "Troponin I measurement: the concept of a precise
immunoassay," Clin. Lab. Internat. 30(5):14-16. cited by applicant
.
Katrukha et al. (1998) "Degradation of cardiac troponin I:
implication for reliable immunodetection," Clin. Chem. 44
(12):2433-2440. cited by applicant .
Reverse Translate a Protein
(www.vivo.colostae.edu/molkit/translate/index.html), Last updated
on Jun. 20, 1998 (Exhibit AA). cited by applicant .
Table showing Codon-amino acid Abbreviations
(www.hgmd.cf.ac.uk/docs/cd.sub.--amino.html) (Exhibit BB). cited by
applicant .
Ylikotila et al. (2006) "Utilization of Recombinant Fab Fragments
in a cTnl Immunoassay Conducted in Spot Wells," Clin. Biochem.
39:843-850. cited by applicant .
Lam, et al., "Microencapsulation of Recombinant Humanized
Monoclonal Antibody for Local Delivery," Proc. Int'l Symp. Control
Rel. Bioact. Mater., vol. 24 pp. 759-760 (1997). cited by applicant
.
Langer, et al,. J. Macromol. Sci. Rev. Macromol. Chem., vol. 23 p.
61 (1983). cited by applicant .
Medical Applications of Controlled Release, Langer and Wise (eds),
CRC Press, Boca Raton, Florida (1974). cited by applicant .
Padlan, et al., Molecular Immunology, vol. 28 (4/5) pp. 489-498
(1991). cited by applicant .
Quinn, F., et al., The Immunoassay Handbook, 2.sup.nd Edition, pp.
363-367 (2001). Riechmann, et al., Nature, vol. 332 p. 323 (1988).
cited by applicant .
Sambrook, et al., A Laboratory Manual, Molecular Cloning, 2.sup.nd
Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
New York (1989). cited by applicant .
Rudikoff et al Proc. Natl. Acad. Sci.USA, 79(6):1979-1983, Mar.
1982. cited by applicant .
Giege, R., et al., Crystallization of Nucleic Acids and Proteins ,
a Practical Approach, 2.sup.nd Edition, pp. 20 1-16, Oxford
University Press, New York, New York (1999). cited by applicant
.
Jefferis, R., et al., Biotechnol. Prog., vol. 21 pp. 11-16 (2005).
cited by applicant .
Kabat, et al., Ann. NY Acad. Sci., vol. 190 pp. 382-391 (1971).
cited by applicant .
Kabat, et al., Sequences of Proteins of Immunological Interest,
5.sup.th Edition, Department of Health and Human Services, NIH
Publication No. 91/3242, USA (1991). cited by applicant .
Hytest 2008 Markers of Cardiovascular Diseases and Metabolic
Syndrome. cited by applicant .
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under
the heading "Fv Structure and Diversity in Three Dimensions". cited
by examiner .
Rudikoff et al Proc. Natl. Acad. Sci.USA, 76(6):1979-1983, Mar.
1982. cited by examiner .
Colman P. M. Research in Immunology, 145:33-36, 1994. cited by
examiner .
Filatov V. L., et al., "Epitope Mapping of Anti-Troponin I
Monoclonal Antibodies, XP000941112," Biochemistry and Molecular
Biology International, 36039, 45 (6), Academic Press, London, GB,
1179-1187. cited by applicant .
PCT International Search Report and Written Opinion of
International Application No. PCT/US2010/024979 mailed on May 6,
2010, 21 pages. cited by applicant .
Peronnet, et al., "Isoelectric point determination of cardiac
troponin I forms present 1n plasma from patients with myocardial
Infarction, NL LNKDD0I: 10.1016/J.CCA.2006.10.006, XP005805375,"
Clinica Chimica Acta, 39066, 377 (1-2), Elsevier BV, Amsterdam,
243-247. cited by applicant .
Rama D., et al., "Epitope Localization of Monoclonal Antibodies
Used in Human Troponin I Immunoenzymometric Assay, XP009033257,"
Hybridoma, 35431, 16 (2), Liebert, New York, NY, US, 153-157. cited
by applicant .
Altshchul, et al., Nucleic Acids Research, vol. 25 pp. 3389-3402
(1997). cited by applicant .
Azzazy, H., et al., Clin. Biochem., vol. 35 pp. 425-445 (2002).
cited by applicant .
Barbas, et al., PNAS, vol. 88 pp. 7978-7982 (1991). cited by
applicant .
Bird, et al., Science, vol. 242 pp. 423-426 (1988). cited by
applicant .
Bodar, et al., Clinical Chemistry, vol. 38 pp. 2203-2214 (1992).
cited by applicant .
Boder, et al., Nature Biotechnology, vol. 15 pp. 553-557 (Jun.
1997). cited by applicant .
Buchwald, et al., Surgery, vol. 88 p. 507 (1980). cited by
applicant .
Carter, et al., Proc. Natl. Acad. Sci., vol. 89 p. 4285, USA
(1992). cited by applicant .
Chothia, et al., J. Mol. Biol., vol. 196 pp. 901-917 (1987). cited
by applicant .
Chothia, et al., J. Mol. Biol., vol. 227 p. 799 (1992). cited by
applicant .
Chothia, et al., Nature, vol. 342 pp. 877-883 (1989). cited by
applicant .
Clackson, et al., Nature, vol. 352 pp. 624-628 (1991). cited by
applicant .
Cleek, et al., "Biodegradable Polymeric Carriers for a bFGF
Antibody for Cardiovascular Application," Pro. Int'l. Symp.
Control. Rel. Bioact. Mater., vol. 24 pp. 853-854 (1997). cited by
applicant .
Co, M.S., et al., Mol. Immunol., vol. 30 pp. 1361-1367 (1993).
cited by applicant .
Controlled Drug Bioavailability, Drug Product Design and
Performance, Smolen and Ball (eds), Wiley, New York (1984). cited
by applicant .
Cummins, et al., Am. Heart Journal, vol. 113 pp. 1333-1344 (1987).
cited by applicant .
During, et al., Ann. Neurol., vol. 25 p. 351 (1989). cited by
applicant .
Foote, et al., J. Mol. Biol., vol. 224 pp. 487-499 (1992). cited by
applicant .
Fuchs, et al., Bio/Technology, vol. 9 pp. 1370-1372 (1991). cited
by applicant .
Garrad, et al., Bio/Technology, vol. 9 pp. 1373-1377 (1991). cited
by applicant .
Gavilondo, J.V., et al., BioTechniques, vol. 29 pp. 128-145 (2000).
cited by applicant .
Giege, R., et al., Crystallization of Nucleic Acids and Proteins ,
a Practical Approach, 2.sup.nd Edition, pp. 20 1-16, Oxford
University Press, New York, New York (1999). cited by applicant
.
Gillies, et al., J. Immunol. Methods, vol. 125 pp. 191-202 (1989).
cited by applicant .
Goodson, et al., Medical Applications of Controlled Release, supra,
vol. 2 pp. 115-138 (1984). cited by applicant .
Gram, et al., PNAS, vol. 89 pp. 3576-3580 (1992). cited by
applicant .
Griffiths, et al., EMBO J., vol. 12 pp. 725-734 (1993). cited by
applicant .
Hay, et al., Hum. Antibod. Hybridomas, vol. 3 pp. 81-85 (1992).
cited by applicant .
Hawkins, et al., J. Mol. Biol., vol. 226 pp. 889-896 (1992). cited
by applicant .
Higgins, et al., CABIOS, 5L151-5L153 (1989). cited by applicant
.
Holliger, P., et al., Proc. Natl. Acad. Sci., vol. 90 pp.
6444-6448, USA (1993). cited by applicant .
Hoogenboom, et al., Nuc. Acid Res., vol. 19 pp. 4133-4137 (1991).
cited by applicant .
Hoogenboom, H.R., et al., TIB Tech., vol. 15 pp. 62-70 (1997).
cited by applicant .
Hoogenboom, H., et al., Immunology Today, vol. 21 pp. 371-378
(2000). cited by applicant .
Howard, et al., J. Neurosurg., vol. 71 p. 105 (1989). cited by
applicant .
Huse, et al., Science, vol. 246 pp. 1275-1281 (1989). cited by
applicant .
Huston, et al., Proc. Natl. Acad. Sci., vol. 85 pp. 5879-5883, USA
(1988). cited by applicant .
Johnsson, B., et al., J. Mol. Recognit., vol. 8 pp. 125-131 (1995).
cited by applicant .
Johnsson, B., et al., Anal. Biochem., vol. 198 pp. 268-277 (1991).
cited by applicant .
Jones, et al., Nature, vol. 321 pp. 522 (1986). cited by applicant
.
Jonsson, U., et al., Biotechniques, vol. 11 pp. 620-627 (1991).
cited by applicant .
Jonsson, U., et al. Ann. Biol. Clin. 51: 19-26 (1993). cited by
applicant .
Kabat, et al., Sequences of Proteins of Immunological Interest,
National Institutes of Health, Bethesda, Maryland (1987) and
(1991). cited by applicant .
Kaufman, R.J., et al., Mol. Biol., vol. 159 pp. 601-621 (1982).
cited by applicant .
Kellermann, S.A., et al., Current Opinion in Biotechnology, vol. 13
pp. 593-597 (2002). cited by applicant .
Kipriyanov, S.M., et al., Human Antibodies and Hybridomas, vol. 6
pp. 93-101 (1995). cited by applicant .
Kipriyanov, S.M., et al., Mol. Immunol., vol. 31 pp. 1047-1058
(1994). cited by applicant .
Kontermann, Antibody Engineering, p. 790, Springer-Verlag, New York
(2001). cited by applicant .
Langer, et al., Science, vol. 249 pp. 1527-1533 (1990). cited by
applicant .
Langer, supra, Sefton, et al., CRC Crit. Ref. Biomed. Eng., vol. 14
p. 20 (1987). cited by applicant .
Levy, et al., Science, vol. 228 p. 190 (1985). cited by applicant
.
Little, M., et al., Immunology Today, vol. 21 pp. 364-370 (2000).
cited by applicant .
MacCallum, et al., J. Mol. Biol., vol. 262 (5) pp. 732-745 (1996).
cited by applicant .
Marchalonis, et al., Adv. Exp. Med. Biol., vol. 484 pp. 13-30
(2001). cited by applicant .
McCafferty, et al., Nature, vol. 348 pp. 552-554 (1990). cited by
applicant .
Mizushima, et al, Nucleic Acids Research, vol. 18 p. 5322 (1990).
cited by applicant .
Morrison, et al., Science, vol. 229 p. 1202 (1985). cited by
applicant .
Morrison, et al., Proc. Natl. Acad. Sci., vol. 81 pp. 851-855
(1984). cited by applicant .
Needleman, et al., J. Mol. Biol., vol. 48 p. 443 (1970). cited by
applicant .
Neuberger, et al., Nature, vol. 312 pp. 604-608 (1984). cited by
applicant .
Ning, et al., "Intratumoral Radioimmunotherapy of a Human Colon
Cancer Xenograft Using a Sustained-Released Gel," Radiotherapy and
Oncology, vol. 39 pp. 179-189 (1996). cited by applicant .
Oi, et al., BioTechniques, vol. 4 p. 214 (1986). cited by applicant
.
Padlan, et al., Faseb J., vol. 9 pp. 133-139 (1995). cited by
applicant .
Pearson, et al., Proc. Natl. Acad. Sci. vol. 85 p. 2444, USA,
(1988). cited by applicant .
Poljak, R.J., et al., Structure, vol. 2 pp. 1121-1123 (1994). cited
by applicant .
Presta, et al., J. Immunol., vol. 151 p. 2623 (1993). cited by
applicant .
Riechmann, et al., Nature, vol. 332 p. 323 (1988). cited by
applicant .
Roguska, et al., PNAS, vol. 91 pp. 969-973 (1994). cited by
applicant .
Saudek, et al., N. Engl. J. Med., vol. 321 p. 574 (1989). cited by
applicant .
Schiestl, et al., Current Genetics, vol. 16 (5-6) pp. 339-346 (Dec.
1989). cited by applicant .
Shapiro, et al., Crit. Rev. Immunol., vol. 22 (3) pp. 183-200
(2002). cited by applicant .
Shields, R.L., et al,. J. Biol. Chem., vol. 277 pp. 26733-26740
(2002). cited by applicant .
Sims, et al., J. Immunol., vol. 151 p. 2296 (1993). cited by
applicant .
Smith, et al., Appl. Math., vol. 2 p. 482 (1981). cited by
applicant .
Song, et al., "Antibody Mediated Lung Targeting of Long-Circulating
Emulsions," PDA Journal of Pharmaceutical Science and Technology,
vol. 50 pp. 372-397 (1995). cited by applicant .
Studnicka, et al., Protein Engineering, vol. 7 (6) pp. 805-814
(1994). cited by applicant .
Takeda, et al., Nature, vol. 314 pp. 452-454 (1985). cited by
applicant .
Taylor, L.D., et al., Nucl. Acids Res., vol. 20 pp. 6287-6295
(1992). cited by applicant .
Umana, et al., Nat. Biotech., vol. 17 pp. 176-181 (1999). cited by
applicant .
Urlaub, et al., Proc. Natl. Acad. Sci., vol. 77 pp. 4216-4220, USA
(1980). cited by applicant .
Verhoeyen, et al., Science, vol. 239 p. 1534 (1988). cited by
applicant .
Wallick, S.C., et al., Exp. Med., vol. 168 pp. 1099-1109 (1988).
cited by applicant .
Ward, et al., Nature, vol. 341 pp. 544-546 (1989). cited by
applicant .
Winnaker, et al., From Genes to Cones, Verlagsgesellschaft,
Weinheim, Germany (1987). cited by applicant .
Wright, A,. et al., EMBO J., vol. 10 pp. 2717-2723 (1991). cited by
applicant .
Wu, et al., J. Biol. Chem., vol. 262 pp. 4429-4432 (1987). cited by
applicant.
|
Primary Examiner: Shafer; Shulamith H
Attorney, Agent or Firm: Mueller; Lisa V. Michael Best &
Friedrich LLP
Claims
What is claimed is:
1. A Chinese Hamster Ovary (CHO) cell line, referred to as TnI 19C7
AM1 hG1CHO 204, designated by American Type Culture Collection
(ATCC) deposit Number PTA-9816.
.[.2. An isolated nucleic acid molecule encoding a binding protein,
wherein the binding protein comprises a variable heavy chain, and
wherein the amino acid sequence of the variable heavy chain of said
binding protein has at least 90% identity to SEQ ID NO:25 and
wherein said binding protein maintains the binding activity of SEQ
ID NO:25..].
.[.3. The isolated nucleic acid molecule of claim 2, wherein the
encoded binding protein further comprises a variable light chain,
and wherein the amino acid sequence of the variable light chain of
said binding protein has at least 90% identity to SEQ ID NO:28 and
wherein said binding protein maintains the binding activity of SEQ
ID NO:28..].
4. An isolated nucleic acid molecule encoding a binding protein,
wherein the binding protein comprises a variable heavy chain, and
wherein the amino acid sequence of the variable heavy chain of said
binding protein is SEQ ID NO:25.
5. An isolated nucleic acid molecule encoding a binding protein,
wherein the binding protein comprises a variable light chain, and
wherein the amino acid sequence of the variable light chain of said
binding protein is SEQ ID NO:28.
6. The isolated nucleic acid molecule of claim 5, wherein said
encoded binding protein further comprises a variable heavy chain,
and wherein the amino acid sequence of the variable heavy chain of
said binding protein is SEQ ID NO:25.
7. A vector comprising said isolated nucleic acid molecule
.Iadd.wherein said isolated nucleic acid molecule encodes a binding
protein, wherein said binding protein comprises the variable heavy
chain .Iaddend.of claim 4 and .Iadd.the variable light chain of
.Iaddend.claim 5.
8. An isolated host cell comprising said vector of claim 7.
9. A method of producing a binding protein capable of binding to
Troponin I, comprising culturing said host cell of claim 8 for a
time and under conditions sufficient to produce said binding
protein.
.Iadd.10. A method of producing a Troponin I binding protein
comprising culturing a host cell referred to as TnI 19C7 AM1 hG1
CHO 204, designated by American Type Culture Collection (ATCC)
deposit Number PTA-9816 under conditions sufficient to produce said
binding protein. .Iaddend.
.Iadd.11. A method of producing a Troponin I binding protein
comprising culturing a host cell that comprises a nucleic acid that
encodes an antibody heavy chain that comprises a CDR1 sequence of
SEQ ID NO:52, a CDR2 sequence of SEQ ID NO: 53, and a CDR3 sequence
of SEQ ID NO:54, and a light chain that comprises a CDR1 sequence
of SEQ ID NO:55, a CDR2 sequence of SEQ ID NO: 56, and a CDR3
sequence of SEQ ID NO:57 under conditions sufficient to produce
said binding protein. .Iaddend.
.Iadd.12. A method of producing a Troponin I binding protein
comprising culturing a host cell that comprises a nucleic acids
that encode the same heavy and light chains as the Chinese Hamster
ovary cell referred to as TnI 19C7 AM1 hG1 CHO 204, designated by
American Type Culture Collection (ATCC) deposit Number PTA-9816
under conditions sufficient to produce said binding protein.
.Iaddend.
Description
.Iadd.CROSS-REFERENCE TO RELATED APPLICATION(S).Iaddend.
.Iadd.This is a reissue of U.S. patent application Ser. No.
12/391,937, filed on Feb. 24, 2009, now U.S. Pat. No.
8,030,026..Iaddend.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The subject invention relates to antibodies to troponin I as well
as methods of use thereof.
2. Background Information
Troponin I is a muscle protein which may be used in the
determination of myocardial damage subsequent to or during, for
example, a myocardial infarction. In particular, troponin I is one
of three subunits of the troponin complex which is located on the
thin filament of the muscle contractile apparatus. This complex has
a primary role in controlling the process of muscle contraction.
The other two subunits (i.e., T and C) are also immobilized on the
thin myofilaments with troponin I in cardiac as well as skeletal
muscle tissue.
Assays have been described which measure cardiac troponin I in
human serum. For example, a radioassay has been used for this
purpose (Cummins et al., Am Heart Journal 113:1333-1344 (1987).
However, the assay utilized polyclonal antibodies having
significant cross-reactivity to skeletal forms of troponin I.
Further, a sandwich assay has been utilized which uses two
different monoclonal antibodies (Bodar et al., Clinical Chemistry
38:2203-2214 (1992); see also U.S. Pat. No. 7,285,418).
Unfortunately, such assays have a very high degree of imprecision.
Thus, the need certainly exists for immunoassays that are highly
specific for and sensitive to troponin I. These immunoassays must
also utilize antibodies which do not possess cross-reactivity to
troponin I found in skeletal tissue. In particular, such
immunoassays are needed so that appropriate therapy can be utilized
by the treating physician thereby giving the affected patient the
best possible prognosis.
All patents and publications referred to herein are hereby
incorporated in their entirety by reference.
SUMMARY OF THE INVENTION
The present invention pertains to binding proteins, particularly
antibodies, capable of binding to cardiac troponin I. In
particular, these antibodies bind to one or more epitopes of
troponin I. Further, the present invention also provides methods of
producing and using these binding proteins or portions thereof, for
example, in diagnostic assays.
In particular, the present invention encompasses a Chinese Hamster
Ovary (CHO) cell line, referred to as TnI 19C7 AM1 hG1 CHO 204,
designated by American Type Culture Collection (ATCC) deposit
number PTA-9816 as well as the recombinant antibody produced by
this cell line.
Additionally, the present invention includes an isolated binding
protein comprising an antigen-binding domain which binds to
Troponin I, said antigen-binding domain comprising at least one
complementarity determining region (CDR) comprising an amino acid
sequence selected from the group consisting of: GYTFTDYNLH (SEQ ID
NO:52), YIYPYNGITGYNQKFKS (SEQ ID NO:53), DAYDYDLTD (SEQ ID NO:54),
RTSKNVGTNIH (SEQ ID NO:55), YASERLP (SEQ ID NO:56) and QQSNNWPYT
(SEQ ID NO:57). The binding protein of the present invention may
include, for example, at least 3 of these CDRs. Further, this
binding protein may also comprise a human acceptor framework or
scaffold. This binding protein may be selected from the group
consisting of, for example, an immunoglobulin molecule, a
monoclonal antibody, a chimeric antibody, a CDR-grafted antibody, a
humanized antibody, a Fab, a Fab', a F(ab')2, a Fv, a disulfide
linked Fv, a scFv, a single domain antibody, a diabody, a
multispecific antibody, a dual specific antibody, an anti-idiotypic
antibody, a bispecific antibody, or a functionally active
epitope-binding fragment of any one of these entities.
The present invention also encompasses an isolated nucleic acid
molecule encoding a binding protein, wherein the amino acid
sequence of the variable heavy chain of the binding protein has at
least 70% identity to SEQ ID NO.: 25 (see FIG. 12). This molecule
may also comprise a variable light chain having at least 70%
identity to SEQ ID NO.: 28 (see FIG. 12).
Furthermore, the present invention includes an isolated nucleic
acid molecule encoding a binding protein, wherein the amino acid
sequence of the variable heavy chain of said binding protein is SEQ
ID NO.:25.
Additionally, the present invention includes an isolated nucleic
acid molecule encoding a binding protein, wherein the amino acid
sequence of the variable light chain of said binding protein is SEQ
ID NO.: 28. The molecule may further comprise an isolated nucleic
acid molecule encoding a variable heavy chain, wherein the amino
acid sequence of the heavy chain is SEQ ID NO.: 25.
The present invention also includes a vector comprising one or more
of the nucleic acid molecules described above, attached to a
regulatory element (e.g., a promoter) as well as a host cell
comprising this vector.
Moreover, the present invention includes a method of producing any
of the binding proteins described above, capable of binding to
Troponin I, which method comprises culturing the host cell,
described above, for a time and under conditions sufficient to
produce the binding protein of interest. The invention also
includes the binding protein produced by this method.
Furthermore, the present invention encompasses a pharmaceutical
composition comprising any one or more of the binding proteins
described above and a pharmaceutically acceptable carrier.
Also, the present invention includes a method of detecting Troponin
I antigen in a test sample. This method comprises the steps of:
contacting the test sample with an antibody which binds to Troponin
I and comprises SEQ ID NO:25 for a time and under conditions
sufficient for the formation of antibody/antigen complexes; and
detecting presence of the complexes, presence of the complexes
indicating presence of Troponin I antigen in said test sample. The
antibody may further comprise SEQ ID NO:28. The antibody may be
produced by a Chinese Hamster Ovary cell line having ATCC deposit
designation PTA-9816.
The present invention also includes a method of detecting Troponin
I antigen in a test sample comprising the steps of: contacting the
test sample with a first antibody which binds to Troponin I and
comprises SEQ ID NO:25 for a time and under conditions sufficient
for the formation of first antibody/antigen complexes; adding a
conjugate to the first antibody/antigen complexes, wherein said
conjugate comprises a second antibody attached to a signal
generating compound capable of generating a detectable signal, for
a time and under conditions sufficient to form first
antibody/antigen/second antibody complexes; and detecting presence
of a signal generating by the signal generating compound, presence
of the signal indicating presence of Troponin I antigen in said
test sample. The first antibody may further comprise SEQ ID NO:28
and may be produced by a Chinese Hamster Ovary cell line having
ATCC deposit designation PTA-9816.
Also, the present invention includes a method of detecting Troponin
I antigen in a test sample comprising the steps of contacting
Troponin I antigen with an antibody to Troponin I for a time and
under conditions sufficient to form Troponin I antigen/antibody
complexes, wherein the antibody comprises SEQ ID NO:25 and is
labeled with a signal-generating compound capable of generating a
detectable signal; adding the test sample to said Troponin I
antigen/antibody complexes for a time and under conditions
sufficient to form Troponin I antigen/antibody/Troponin I test
sample antigen complexes; and detecting presence of a signal
generating by the signal generating compound, presence of the
signal indicating presence of Troponin I antigen in the test
sample. Again, the antibody may further comprise SEQ ID NO:28 and
may be produced by a Chinese Hamster Ovary cell line having ATCC
deposit designation PTA-9816.
The present invention also encompasses another method of detecting
Troponin I antigen in a test sample. This method comprises the
steps of: contacting the test sample with 1) a Troponin I reference
antigen, wherein the antigen is attached to a signal generating
compound capable of generating a detectable signal and 2) an
antibody to Troponin I antigen wherein the antibody comprises SEQ
ID NO:25, for a time and under conditions sufficient to form
Troponin I reference antigen/antibody complexes; and detecting a
signal generated by the signal generating compound, wherein the
amount of Troponin I antigen detected in the test sample is
inversely proportional to the amount of Troponin I reference
antigen bound to the antibody. Again, the antibody may further
comprise SEQ ID NO:28 and may be produced by a Chinese Hamster
Ovary cell line having ATCC deposit designation PTA-9816.
In addition, the present invention includes pharmaceutical
composition comprising any one or more of the binding proteins
described above and a pharmaceutically acceptable carrier.
The present invention also encompasses a method of diagnosing acute
coronary syndrome or myocardial infarction in a patient suspected
of having one of these conditions. This method comprises the steps
of: isolating a biological sample from the patient; contacting the
biological sample with an antibody which binds to Troponin I and
comprises SEQ ID NO:25, for a time and under conditions sufficient
for formation of Troponin I antigen/antibody complexes; detecting
presence of the Troponin I antigen/antibody complexes; dissociating
the Troponin I antigen present in the complexes from the antibody
present in said complexes; and measuring the amount of dissociated
Troponin I antigen, wherein an amount of Troponin I antigen greater
than approximately 1-5 times the Troponin I value of the 99.sup.th
percentile of a normal population indicates a diagnosis of acute
coronary syndrome or myocardial infarction in the patient.
The present invention includes an additional method method of
diagnosing acute coronary syndrome or myocardial infarction in a
patient suspected of having one of these conditions. This method
comprises the steps of: isolating a biological sample from the
patient; contacting the biological sample with a first antibody
which binds to Troponin I and comprises SEQ ID NO:25, for a time
and under conditions sufficient for the formation of Troponin I
antigen/antibody complexes; adding a conjugate to the resulting
Troponin I antigen/antibody complexes for a time and under
conditions sufficient to allow the conjugate to bind to the bound
Troponin I antigen, wherein the conjugate comprises a second
antibody attached to a signal generating compound capable of
generating a detectable signal; detecting the presence of Troponin
I antigen which may be present in said biological sample by
detecting a signal generated by said signal generating compound;
and measuring the amount of Troponin I antigen present in the test
sample by measuring the intensity of the signal, an amount of
Troponin I antigen greater than approximately 1-5 times the value
of the 99.sup.th percentile of a normal population indicating a
diagnosis of acute coronary syndrome or myocardial infarction in
the patient.
The present invention also includes a kit comprising any one or
more of the monoclonal antibodies or binding proteins described
above and, if needed, instructions describing the manner in which
to use this kit.
Additionally, the present invention includes an isolated binding
protein which comprises an antigen-binding domain, wherein the
antigen-binding domain comprises at least one CDR comprising an
amino acid sequence selected from the group consisting of:
CDR-VH1.
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8--
X.sub.9-X.sub.10 (SEQ ID NO:63), wherein: X.sub.1 is G; X.sub.2 is
Y; X.sub.3 is T or S; X.sub.4 is F; X.sub.5 is T; X.sub.6 is D;
X.sub.7 is Y; X.sub.8 is N; X.sub.9 is I or L; and X.sub.10 is
H.
CDR-VH2.
X.sub.1X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X-
.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-X.sub.15-X.sub-
.16-X.sub.17 (SEQ ID NO:64), wherein: X.sub.1 is Y; X.sub.2 is I;
X.sub.3 is Y; X.sub.4 is P; X.sub.5 is Y; X.sub.6 is N; X.sub.7 is
G; X.sub.8 IS I; X.sub.9 is T; X.sub.10 is G; X.sub.11 is Y;
X.sub.12 is N; X.sub.13 is Q; X.sub.14 is K; X.sub.15 is F;
X.sub.16 is K; and X.sub.17 is S.
CDR-VH3.
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8--
X.sub.9-X.sub.10 (SEQ ID NO:65), wherein: X.sub.1 is D; X.sub.2 is
A or F; X.sub.3 is Y; X.sub.4 is D; X.sub.5 is Y or S; X.sub.6 is
D; X.sub.7 is W, Y or A; X.sub.8 is L; X.sub.9 is A or T; and
X.sub.10 is Y or D.
CDR-VL1.
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8--
X.sub.9-X.sub.10-X.sub.11 (SEQ ID NO:66), wherein: X.sub.1 is R;
X.sub.2 is A or T; X.sub.3 is S; X.sub.4 is Q or K; X.sub.5 is S or
N; X.sub.6 is I or V; X.sub.7 is G; X.sub.8 is T; X.sub.9 is N;
X.sub.10 is I; and X.sub.11 is Y or H.
CDR-VL2. X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7
(SEQ ID NO:67), wherein: X.sub.1 is Y; X.sub.2 is A or G; X.sub.3
is S or T; X.sub.4 is E; X.sub.5 is S or R; X.sub.6 is I, L or V;
and X.sub.7 is S, P or F, and
CDR-VL3.
X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8--
X.sub.9 (SEQ ID NO:68), wherein: X.sub.1 is Q; X.sub.2 is Q;
X.sub.3 is S; X.sub.4 is N; X.sub.5 is N; X.sub.6 is W; X.sub.2 is
P; X.sub.8 is Y; and X.sub.9 is T.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 is a flow chart showing the steps used to identify and
create antibodies that have improved affinity for troponin I.
FIG. 2 is the nucleotide description (SEQ ID NO: 109 and SEQ ID NO:
110) of the wild-type TnI 19C7 single-chain variable fragment
("scFv").
FIG. 3 shows that yeast expressing full-length TnI 19C7
single-chain variable fragment (scFv) bind to single chain troponin
I (28-110aa)-linker-troponin C known as scTnI-C-2 (Spectral
diagnostics, RP-3700). More specifically, this figure shows that
TnI 19C7 scFv expressing yeast were incubated with scTnI-C-2 or
anti-V5, followed by either anti-troponin mAb and goat anti
mouse-phycoerythrin (GAM:PE) (FIG. 3B) or GAM:PE respectively (FIG.
3A). The flow cytometry histograms illustrate the full-length
expression of TnI 19C7 scFv as detected by anti-V5 and the ability
of TnI 19C7 scFv to bind to scTnI-C-2. PE-A units (abscissa).
10.sup.2, 10.sup.3, 10.sup.4, and 10.sup.5. Count units (ordinate):
10.sup.2, 10.sup.3, 10.sup.4, and 10.sup.5.
FIG. 4 shows the TnI 19C7 scFv off-rate measurement. More
specifically, yeast expressing TnI 19C7 scFv were incubated with a
saturating concentration of scTnI-C-2. Cells were washed twice and
at each time point, cells were transferred to ice, washed and
incubated with anti-TnI mAb. After 30 minutes, cells were washed
again and incubated with goat anti-mouse phycoerythrin. Again after
30 minutes, cells were washed and analyzed on the flow cytometer. A
first order decay equation was used to fit the individual time
points where ml was the theoretical maximum mean fluorescence units
("MFU") at time 0, m2 was the off-rate ("koff"), m3 was the
background MFU due to autofluorescence and M0, which is the time x
(the x being the time that is being measured) was the time x that
measurements are taken. The half-life (t.sub.1/2) of TnI 19C7 scFv
binding to TnI-C-2 was calculated using: t.sub.1/2=ln 2/k.sub.off.
Five times the half-life was the time used to sort the TnI 19C7
scFv CDR mutagenic libraries.
FIG. 5 shows the TnI 19C7 scFv equilibrium dissociation constant
(KD) measurement. More specifically, yeast expressing TnI 19C7 scFv
were incubated with varying concentrations of scTnI-C-2. Cells were
washed twice with PBS pH6.8/2% BSA/0.02% Standapol ES-1 and
incubated with anti-TnI mAb for 30 min Cells were washed again and
incubated with goat anti-mouse phycoerythrin for 30 min. Finally,
cells were washed and analyzed on the flow cytometer.
FIG. 6 is a schematic depiction that shows how degenerate
oligonucleotides were designed so that primers are made such that
for each CDR nucleotide residue 70% remains the wild-type residue
and 30% a mix of the other three residues. Two PCR products are
generated for each library a spiked (sp) PCR product and a
non-spiked PCR product. The spiked and non-spiked PCR products are
combined to generate an intact CDR mutagenized scFv library.
FIG. 7 is a schematic depiction that shows how the TnI 19C7 scFv
library was constructed using yeast homologous recombination. More
specifically, the spiked CDR PCR product and the excised yeast
display vector were transformed into S. cerevisiae strain EBY100.
Transformed clones were selected in tryptophan deficient glucose
media.
FIG. 8 is a summary showing the PCR primers that were used to
generate the scFv construct (tpVHfor through tpVL-rev), those used
to generate the CDR spiked libraries (19H1spfor through pYD41rev2)
and those used to generate the combination library (19FRH2for to
19FRL3) (see SEQ ID Nos:1-22). The bold and enlarged areas of the
primers represent those regions in which a "70% wild-type, 30%
other nucleotide mixture" was incorporated while the primers were
being made. Such a "spiked" primer generated the diversity within
the library.
FIG. 9 shows equilibrium dissociation constant (KD) measurements of
selected TnI 19C7 scFv determined as described above in FIG. 5.
FIG. 10 shows the results of relative antibody affinity as measured
as an antigen 50% (Ag50). Four TnI 19C7 clones were converted into
mouse IgG2ak antibodies by cloning the variable domains onto the
immunoglobulin constant domains. Antibodies were expressed in a
transient HEK 294 cell system. The Ag50 is the concentration of
scTnI-C at which is 50% of the maximum signal and represents the
relative affinity ranking of the selected TnI 19C7 AM candidates.
TnI 19C7 AM1 exemplifies the tightest relative affinity compared to
the TnI 19C7 wild-type antibody.
FIG. 11 illustrates TnI 19C7 AM1's ability to bind to scTnI-C in an
ARCHITECT.RTM. assay format (Abbott Laboratories, Abbott Park,
Ill.). TnI 19C7 was labeled with acridinium and assayed for binding
to scTnI-C using anti-TnI capture beads. (X=signal generated with
given calibrator concentration of scTnI-C; X/A=ratio of calibrator
X signal to calibrator A signal; RLU=Relative Light Units). TnI
19C7 AM1 exhibited better binding in this assay format for the
range of calibrators compared to the wild-type TnI 19C7
antibody.
FIG. 12 illustrates the nucleotide (SEQ ID NO:23, SEQ ID NO:24
(complement), SEQ ID NO:26 and SEQ ID NO:27 (complement)) and
encoded amino acid sequences of the heavy (SEQ ID NO:25) and light
(SEQ ID NO:28) chains of monoclonal antibody TnI 19C7 AM1 and, in
particular, of the complementarity determining regions (CDRs).
FIG. 13 illustrates the positions within the heavy and light chains
of the TnI 19C7 CDRs that may be substituted with amino acids other
than those shown in FIG. 12 (SEQ ID Nos: 30-49).
DETAILED DESCRIPTION OF THE INVENTION
Unless otherwise defined herein, scientific and technical terms
used in connection with the present invention shall have the
meanings that are commonly understood by those of ordinary skill in
the art. The meaning and scope of the terms should be clear;
however, in the event of any latent ambiguity, definitions provided
herein take precedent over any dictionary or extrinsic definition.
Further, unless otherwise required by context, singular terms shall
include pluralities and plural terms shall include the singular. In
this application, the use of "or" means "and/or" unless stated
otherwise. Furthermore, the use of the term "including", as well as
other forms, such as "includes" and "included", is not limiting.
Also, terms such as "element" or "component" encompass both
elements and components comprising one unit and elements and
components that comprise more than one subunit unless specifically
stated otherwise.
Generally, nomenclatures-used in connection with, and techniques
of, cell and tissue culture, molecular biology, immunology,
microbiology, genetics and protein and nucleic acid chemistry and
hybridization described herein are those well known and commonly
used in the art. The methods and techniques of the present
invention are generally performed according to conventional methods
well known in the art and as described in various general and more
specific references that are cited and discussed throughout the
present specification unless otherwise indicated. Enzymatic
reactions and purification techniques are performed according to
manufacturer's specifications, as commonly accomplished in the art
or as described herein. The nomenclatures used in connection with,
and the laboratory procedures and techniques of, analytical
chemistry, synthetic organic chemistry, and medicinal and
pharmaceutical chemistry described herein are those well known and
commonly used in the art. Standard techniques are used for chemical
syntheses, chemical analyses, pharmaceutical preparation,
formulation, and delivery, and treatment of patients.
In order that the present invention may be more readily understood,
select terms are defined below.
The term "polypeptide" as used herein, refers to any polymeric
chain of amino acids. The terms "peptide" and "protein" are used
interchangeably with the term polypeptide and also refer to a
polymeric chain of amino acids. The term "polypeptide" encompasses
native or artificial proteins, protein fragments and polypeptide
analogs of a protein sequence. A polypeptide may be monomeric or
polymeric.
The term "isolated protein" or "isolated polypeptide" is a protein
or polypeptide that by virtue of its origin or source of derivation
is not associated with naturally associated components that
accompany it in its native state; is substantially free of other
proteins from the same species; is expressed by a cell from a
different species; or does not occur in nature. Thus, a polypeptide
that is chemically synthesized or synthesized in a cellular system
different from the cell from which it naturally originates will be
"isolated" from its naturally associated components. A protein may
also be rendered substantially free of naturally associated
components by isolation, using protein purification techniques well
known in the art.
The term "recovering" as used herein, refers to the process of
rendering a chemical species such as a polypeptide substantially
free of naturally associated components by isolation, e.g., using
protein purification techniques well known in the art.
The subject invention also includes isolated nucleotide sequences
(or fragments thereof) encoding the variable light and heavy chains
of the antibodies described herein as well as those nucleotide
sequences (or fragments thereof) having sequences comprising,
corresponding to, identical to, hybridizable to, or complementary
to, at least about 70% (e.g., 70% 71%, 72%, 73%, 74%, 75%, 76%,
77%, 78% or 79%), preferably at least about 80% (e.g., 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88% or 89%), and more preferably at
least about 90% (e.g, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%
or 100%) identity to these encoding nucleotide sequences. (All
integers (and portions thereof) between and including 70% and 100%
are considered to be within the scope of the present invention with
respect to percent identity.) Such sequences may be derived from
any source (e.g., either isolated from a natural source, produced
via a semi-synthetic route, or synthesized de novo). In particular,
such sequences may be isolated or derived from sources other than
described in the examples (e.g., bacteria, fungus, algae, mouse or
human).
In addition to the nucleotide sequences described above, the
present invention also includes amino acid sequences of the
variable light and heavy chains of the antibodies described herein
(or fragments of these amino acid sequences). Further, the present
invention also includes amino acid sequences (or fragments thereof)
comprising, corresponding to, identical to, or complementary to at
least about 70% (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%
or 79%), preferably at least about 80% (e.g., 80% 81%, 82%, 83%,
84%, 85%, 86%, 87%, 88% or 89%), and more preferably at least about
90% identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99% or 100%), to the amino acid sequences of the proteins of the
present invention. (Again, all integers (and portions thereof)
between and including 70% and 100% (as recited in connection with
the nucleotide sequence identities noted above) are also considered
to be within the scope of the present invention with respect to
percent identity.)
For purposes of the present invention, a "fragment" of a nucleotide
sequence is defined as a contiguous sequence of approximately at
least 6, preferably at least about 8, more preferably at least
about 10 nucleotides, and even more preferably at least about 15
nucleotides corresponding to a region of the specified nucleotide
sequence.
The term "identity" refers to the relatedness of two sequences on a
nucleotide-by-nucleotide basis over a particular comparison window
or segment. Thus, identity is defined as the degree of sameness,
correspondence or equivalence between the same strands (either
sense or antisense) of two DNA segments (or two amino acid
sequences). "Percentage of sequence identity" is calculated by
comparing two optimally aligned sequences over a particular region,
determining the number of positions at which the identical base or
amino acid occurs in both sequences in order to yield the number of
matched positions, dividing the number of such positions by the
total number of positions in the segment being compared and
multiplying the result by 100. Optimal alignment of sequences may
be conducted by the algorithm of Smith & Waterman, Appl. Math.
2:482 (1981), by the algorithm of Needleman & Winch, J. Mol.
Biol. 48:443 (1970), by the method of Pearson & Lipmann, Proc.
Natl. Acad. Sci. (USA) 85:2444 (1988) and by computer programs
which implement the relevant algorithms (e.g., Crustal Macaw Pileup
(Higgins et al., CABIOS. 5L151-153 (1989)), FASTDB
(Intelligentsias), BLAST (National Center for Biomedical
Information; Latches et al., Nucleic Acids Research 25:3389-3402
(1997)), PILEUP (Genetics Computer Group, Madison, Wis.) or GAP,
BESTFIT, FASTA and TFASTA (Wisconsin Genetics Software Package
Release 7.0, Genetics Computer Group, Madison, Wis.). (See U.S.
Pat. No. 5,912,120.)
For purposes of the present invention, "complementarity" is defined
as the degree of relatedness between two DNA segments. It is
determined by measuring the ability of the sense strand of one DNA
segment to hybridize with the antisense strand of the other DNA
segment, under appropriate conditions, to form a double helix. A
"complement" is defined as a sequence which pairs to a given
sequence based upon the canonic base-pairing rules. For example, a
sequence A-G-T in one nucleotide strand is "complementary" to T-C-A
in the other strand.
In the double helix, adenine appears in one strand, thymine appears
in the other strand. Similarly, wherever guanine is found in one
strand, cytosine is found in the other. The greater the relatedness
between the nucleotide sequences of two DNA segments, the greater
the ability to form hybrid duplexes between the strands of the two
DNA segments.
"Similarity" between two amino acid sequences is defined as the
presence of a series of identical as well as conserved amino acid
residues in both sequences. The higher the degree of similarity
between two amino acid sequences, the higher the correspondence,
sameness or equivalence of the two sequences. ("Identity between
two amino acid sequences is defined as the presence of a series of
exactly alike or invariant amino acid residues in both sequences.)
The definitions of "complementarity", "identity" and "similarity"
are well known to those of ordinary skill in the art.
"Encoded by" refers to a nucleic acid sequence which codes for a
polypeptide sequence, wherein the polypeptide sequence or a portion
thereof contains an amino acid sequence of at least 3 amino acids,
more preferably at least 8 amino acids, and even more preferably at
least 15 amino acids from a polypeptide encoded by the nucleic acid
sequence.
"Biological activity" as used herein, refers to all inherent
biological properties of an antibody against troponin I or troponin
I. Such properties include, for example, the ability of the
antibody to bind to troponin I and functionally-related antibodies
described herein.
The terms "specific binding" or "specifically binding", as used
herein, in reference to the interaction of an antibody, a protein,
or a peptide with a second chemical species, mean that the
interaction is dependent upon the presence of a particular
structure (e.g., an antigenic determinant or epitope) on the
chemical species; for example, an antibody recognizes and binds to
a specific protein structure rather than to proteins generally. If
an antibody is specific for epitope "A", the presence of a molecule
containing epitope A (or free, unlabeled A), in a reaction
containing labeled "A" and the antibody, will reduce the amount of
labeled A bound to the antibody.
The term "antibody", as used herein, broadly refers to any
immunoglobulin (Ig) molecule comprised of four polypeptide chains,
two heavy (H) chains and two light (L) chains, or any functional
fragment, mutant, variant, or derivation thereof, which retains the
essential epitope binding features of an Ig molecule. Such mutant,
variant, or derivative antibody entities are known in the art,
non-limiting embodiments of which are discussed below.
In a full-length antibody, each heavy chain is comprised of a heavy
chain variable region (abbreviated herein as HCVR or VH) and a
heavy chain constant region. The heavy chain constant region is
comprised of three domains, CH1, CH2 and CH3. Each light chain is
comprised of a light chain variable region (abbreviated herein as
LCVR or VL) and a light chain constant region. The light chain
constant region is comprised of one domain, CL. The VH and VL
regions can be further subdivided into regions of hypervariability,
termed complementarity determining regions (CDR), interspersed with
regions that are more conserved, termed framework regions (FR).
Each VH and VL is composed of three CDRs and four FRs, arranged
from amino-terminus to carboxy-terminus in the following order:
FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Immunoglobulin molecules can
be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class
(e.g., IgG 1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass and may
be from any species (e.g., mouse, human, chicken, rat, rabbit,
sheep, shark and camelid).
The CDRs of the antibodies of the present invention are shown in
Tables 1 and 2 below:
TABLE-US-00001 TABLE 1 CDRs OF HEAVY CHAIN FOR TnI 19C7 AM1 SEQ ID
NO. Protein region Sequence 52 CDR H1 GYTFTDYNLH 53 CDR H2
YIYPYNGITGYNQKFKS 54 CDR H3 DAYDYDYLTD
TABLE-US-00002 TABLE 2 CDRs OF LIGHT CHAIN FOR TnI 19C7 AM1 SEQ ID
NO. Protein region Sequence 55 CDR Ll RTSKNVGTNIH 56 CDR L2 YASERLP
57 CDR L3 QQSNNWPYT
The term "antigen-binding portion" of an antibody (or simply
"antibody portion"), as used herein, refers to one or more
fragments of an antibody that retain the ability to specifically
bind to an antigen. It has been shown that the antigen-binding
function of an antibody can be performed by one or more fragments
of a full-length antibody. Such antibody embodiments may also be
bispecific, dual specific, or multi-specific, specifically binding
to two or more different antigens. Examples of binding fragments
encompassed within the term "antigen-binding portion" of an
antibody include (i) a Fab fragment, a monovalent fragment
consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab').sub.2
fragment, a bivalent fragment comprising two Fab fragments linked
by a disulfide bridge at the hinge region; (iii) a Fd fragment
consisting of the VH and CH1 domains; (iv) a Fv fragment consisting
of the VL and VH domains of a single arm of an antibody, (v) a dAb
fragment (Ward et al., (1989) Nature 341:544-546, Winter et al.,
Intern. Appln. Public. No. WO 90/05144 A1 herein incorporated by
reference), which comprises a single variable domain; and (vi) an
isolated complementarity determining region (CDR). Furthermore,
although the two domains of the Fv fragment, VL and VH, are coded
for by separate genes, they can be joined, using recombinant
methods, by a synthetic linker that enables them to be made as a
single protein chain in which the VL and VH regions pair to form
monovalent molecules (known as single chain Fv (scFv); see e.g.,
Bird et al. (1988) Science 242:423-426; and Huston et al. (1988)
Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain
antibodies are also encompassed herein within the term
"antigen-binding portion" of an antibody. Other forms of single
chain antibodies, such as diabodies, are also encompassed.
Diabodies are bivalent, bispecific antibodies in which VH and VL
domains are expressed on a single polypeptide chain, but using a
linker that is too short to allow for pairing between the two
domains on the same chain, thereby forcing the domains to pair with
complementary domains of another chain and creating two antigen
binding sites (see e.g., Holliger, P., et al. (1993) Proc. Natl.
Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure
2:1121-1123). Such antibody binding portions are known in the art
(Kontermann and Dubel eds., Antibody Engineering (2001)
Springer-Verlag. New York. 790 pp. (ISBN 3-540-41354-5).
The term "antibody construct" as used herein refers to a
polypeptide comprising one or more the antigen binding portions of
the invention linked to a linker polypeptide or an immunoglobulin
constant domain. Linker polypeptides comprise two or more amino
acid residues joined by peptide bonds and are used to link one or
more antigen binding portions. Such linker polypeptides are well
known in the art (see e.g., Holliger, P., et al. (1993) Proc. Natl.
Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure
2:1121-1123). An immunoglobulin constant domain refers to a heavy
or light chain constant domain. Human IgG heavy chain and light
chain constant domain amino acid sequences are known in the art,
and examples are presented in Table 3.
TABLE-US-00003 TABLE 3 SEQUENCE OF HUMAN IgG HEAVY CHAIN CONSTANT
DOMAIN AND LIGHT CHAIN CONSTANT DOMAIN Se- quence Identi- Sequence
Protein fier 12345678901234567890123456789012 Ig SEQ ID
ASTKGPSVFFLAPSSKSTSGGTAALGCLVKDYFP gamma-1 NO.: 50
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV constant
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS region
CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK Ig SEQ
ID ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP gamma-1 NO.: 51
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV constant
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS region
CDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMI mutant
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK Ig
Kappa SEQ ID TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR constant NO.: 61
EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS region
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC Ig SEQ ID
QPKAAPSVTLFPPSSEELQANKATLVCLISDFYP Lambda NO.: 62
GAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAS constant
SYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPT region ECS
Still further, an antibody or antigen-binding portion thereof may
be part of a larger immunoadhesion molecule, formed by covalent or
noncovalent association of the antibody or antibody portion with
one or more other proteins or peptides. Examples of such
immunoadhesion molecules include use of the streptavidin core
region to make a tetrameric scFv molecule (Kipriyanov, S. M., et
al. (1995) Human Antibodies and Hybridomas 6:93-101) and use of a
cysteine residue, a marker peptide and a C-terminal polyhistidine
tag to make bivalent and biotinylated scFv molecules (Kipriyanov,
S. M., et al. (1994) Mol. Immunol. 31:1047-1058). Antibody
portions, such as Fab and F(ab').sub.2 fragments, can be prepared
from whole antibodies using conventional techniques, such as papain
or pepsin digestion, respectively, of whole antibodies. Moreover,
antibodies, antibody portions and immunoadhesion molecules can be
obtained using standard recombinant DNA techniques, as described
herein.
An "isolated antibody", as used herein, is intended to refer to an
antibody that is substantially free of other antibodies having
different antigenic specificities (e.g., an isolated antibody that
specifically binds troponin I is substantially free of antibodies
that specifically bind antigens other than troponin I). An isolated
antibody that specifically binds troponin I may, however, have
cross-reactivity to other antigens, such as troponin I molecules
from other species. Moreover, an isolated antibody may be
substantially free of other cellular material and/or chemicals.
The term "human antibody", as used herein, is intended to include
antibodies having variable and constant regions derived from human
germline immunoglobulin sequences. The human antibodies of the
invention may include amino acid residues not encoded by human
germline immunoglobulin sequences (e.g., mutations introduced by
random or site-specific mutagenesis in vitro or by somatic mutation
in vivo), for example in the CDRs and in particular CDR3. However,
the term "human antibody", as used herein, is not intended to
include antibodies in which CDR sequences derived from the germline
of another mammalian species, such as a mouse, have been grafted
onto human framework sequences.
The term "recombinant human antibody", as used herein, is intended
to include all human antibodies that are prepared, expressed,
created or isolated by recombinant means, such as antibodies
expressed using a recombinant expression vector transfected into a
host cell (described below), antibodies isolated from a
recombinant, combinatorial human antibody library (Hoogenboom H.
R., (1997) TIB Tech. 15:62-70; Azzazy H., and Highsmith W. E.,
(2002) Clin. Biochem. 35:425-445; Gavilondo J. V., and Larrick J.
W. (2002) BioTechniques 29:128-145; Hoogenboom H., and Chames P.
(2000) Immunology Today 21:371-378), antibodies isolated from an
animal (e.g., a mouse) that is transgenic for human immunoglobulin
genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res.
20:6287-6295; Kellermann, S-A. and Green, L. L. (2002) Current
Opinion in Biotechnology 13:593-597; Little M. et al (2000)
Immunology Today 21:364-370) or antibodies prepared, expressed,
created or isolated by any other means that involves splicing of
human immunoglobulin gene sequences to other DNA sequences. Such
recombinant human antibodies have variable and constant regions
derived from human germline immunoglobulin sequences. In certain
embodiments, however, such recombinant human antibodies are
subjected to in vitro mutagenesis (or, when an animal transgenic
for human Ig sequences is used, in vivo somatic mutagenesis) and
thus the amino acid sequences of the VH and VL regions of the
recombinant antibodies are sequences that, while derived from and
related to human germline VH and VL sequences, may not naturally
exist within the human antibody germline repertoire in vivo.
The term "chimeric antibody" refers to antibodies which comprise
heavy and light chain variable region sequences from one species
and constant region sequences from another species. The present
invention encompasses chimeric antibodies having, for example,
murine heavy and light chain variable regions linked to human
constant regions.
The term "CDR-grafted antibody" refers to antibodies which comprise
heavy and light chain variable region sequences from one species
but in which the sequences of one or more of the CDR regions of VH
and/or VL are replaced with CDR sequences of another species, such
as antibodies having murine heavy and light chain variable regions
in which one or more of the murine CDRs (e.g., CDR3) has been
replaced with human CDR sequences.
The term "humanized antibody" refers to antibodies which comprise
heavy and light chain variable region sequences from a non-human
species (e.g., a mouse) but in which at least a portion of the VH
and/or VL sequence has been altered to be more "human-like", i.e.,
more similar to human germline variable sequences. One type of
humanized antibody is a CDR-grafted antibody, in which human CDR
sequences are introduced into non-human VH and VL sequences to
replace the corresponding nonhuman CDR sequences.
The terms "Kabat numbering", "Kabat definitions and "Kabat
labeling" are used interchangeably herein. These terms, which are
recognized in the art, refer to a system of numbering amino acid
residues which are more variable (i.e. hypervariable) than other
amino acid residues in the heavy and light chain variable regions
of an antibody, or an antigen binding portion thereof (Kabat et al.
(1971) Ann. NY Acad, Sci. 190:382-391 and Kabat, E. A., et al.
(1991) Sequences of Proteins of Immunological Interest, Fifth
Edition, U.S. Department of Health and Human Services, NIH
Publication No. 91-3242). For the heavy chain variable region, the
hypervariable region ranges from amino acid positions 31 to 35 for
CDR1, amino acid positions 50 to 65 for CDR2, and amino acid
positions 95 to 102 for CDR3. For the light chain variable region,
the hypervariable region ranges from amino acid positions 24 to 34
for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid
positions 89 to 97 for CDR3. (In addition, for purposes of the
present invention, the AbM definition as defined by Oxford
Molecular's ABM antibody modeling software was used to define the
CDR-H1 region from amino acids 26-35 for the heavy chain.)
As used herein, the terms "acceptor" and "acceptor antibody" refer
to the antibody or nucleic acid sequence providing or encoding at
least 80%, at least 85%, at least 90%, at least 95%, at least 98%
or 100% of the amino acid sequences of one or more of the framework
regions. In some embodiments, the term "acceptor" refers to the
antibody amino acid or nucleic acid sequence providing or encoding
the constant region(s). In yet another embodiment, the term
"acceptor" refers to the antibody amino acid or nucleic acid
sequence providing or encoding one or more of the framework regions
and the constant region(s). In a specific embodiment, the term
"acceptor" refers to a human antibody amino acid or nucleic acid
sequence that provides or encodes at least 80%, preferably, at
least 85%, at least 90%, at least 95%, at least 98%, or 100% of the
amino acid sequences of one or more of the framework regions. In
accordance with this embodiment, an acceptor may contain at least
1, at least 2, at least 3, least 4, at least 5, or at least 10
amino acid residues that does (do) not occur at one or more
specific positions of a human antibody. An acceptor framework
region and/or acceptor constant region(s) may be, e.g., derived or
obtained from a germline antibody gene, a mature antibody gene, a
functional antibody (e.g., antibodies well-known in the art,
antibodies in development, or antibodies commercially
available).
As used herein, the term "CDR" refers to the complementarity
determining region within antibody variable sequences. There are
three CDRs in each of the variable regions of the heavy chain and
the light chain, which are designated CDR1, CDR2 and CDR3, for each
of the variable regions. The term "CDR set" as used herein refers
to a group of three CDRs that occur in a single variable region
capable of binding the antigen. The exact boundaries of these CDRs
have been defined differently according to different systems. The
system described by Kabat (Kabat et al., Sequences of Proteins of
Immunological Interest (National Institutes of Health, Bethesda,
Md. (1987) and (1991)) not only provides an unambiguous residue
numbering system applicable to any variable region of an antibody,
but also provides precise residue boundaries defining the three
CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and
coworkers (Chothia & Lesk, J. Mol. Biol. 196:901-917 (1987) and
Chothia et al., Nature 342:877-883 (1989)) found that certain
sub-portions within Kabat CDRs adopt nearly identical peptide
backbone conformations, despite having great diversity at the level
of amino acid sequence. These sub-portions were designated as L1,
L2 and L3 or H1, H2 and H3 where the "L" and the "H" designates the
light chain and the heavy chains regions, respectively. These
regions may be referred to as Chothia CDRs, which have boundaries
that overlap with Kabat CDRs. Other boundaries defining CDRs
overlapping with the Kabat CDRs have been described by Padlan
(FASEB J. 9:133-139 (1995)) and MacCallum (J Mol Biol 262(5):732-45
(1996)). Still other CDR boundary definitions may not strictly
follow one of the above systems, such as AbM definitions, but will
nonetheless overlap with the Kabat CDRs, although they may be
shortened or lengthened in light of prediction or experimental
findings that particular residues or groups of residues or even
entire CDRs do not significantly impact antigen binding. The
methods used herein may utilize CDRs defined according to any of
these systems, although preferred embodiments use Kabat, AbM or
Chothia defined CDRs.
As used herein, the term "canonical" residue refers to a residue in
a CDR or framework that defines a particular canonical CDR
structure as defined by Chothia et al. (J. Mol. Biol. 196:901-907
(1987); Chothia et al., J. Mol. Biol. 227: 799 (1992), both are
incorporated herein by reference). According to Chothia et al.,
critical portions of the CDRs of many antibodies have nearly
identical peptide backbone confirmations despite great diversity at
the level of amino acid sequence. Each canonical structure
specifies primarily a set of peptide backbone torsion angles for a
contiguous segment of amino acid residues forming a loop.
As used herein, the terms "donor" and "donor antibody" refer to an
antibody providing one or more CDRs. In a preferred embodiment, the
donor antibody is an antibody from a species different from the
antibody from which the framework regions are obtained or derived.
In the context of a humanized antibody, the term "donor antibody"
refers to a non-human antibody providing one or more CDRs.
As used herein, the term "framework" or "framework sequence" refers
to the remaining sequences of a variable region minus the CDRs.
Because the exact definition of a CDR sequence can be determined by
different systems, the meaning of a framework sequence is subject
to correspondingly different interpretations. The six CDRs (CDR-L1,
-L2, and -L3 of light chain and CDR-H1, -H2, and -H3 of heavy
chain) also divide the framework regions on the light chain and the
heavy chain into four sub-regions (FR1, FR2, FR3 and FR4) on each
chain, in which CDR1 is positioned between FR1 and FR2, CDR2
between FR2 and FR3, and CDR3 between FR3 and FR4. Without
specifying the particular sub-regions as FR1, FR2, FR3 or FR4, a
framework region, as referred by others, represents the combined
FR's within the variable region of a single, naturally occurring
immunoglobulin chain. As used herein, a FR represents one of the
four sub-regions, and FRs represents two or more of the four
sub-regions constituting a framework region.
In one embodiment of the invention, the murine heavy chain and
light chain donor sequences are selected from the sequences
described below:
TABLE-US-00004 TABLE 4 HEAVY CHAIN DONOR SEQUENCES FOR TnI 19C7 AM1
Sequence SEQ ID No. 12345678901234567890123456789012 69
EVTLRESGPALVKPTQTLTLTCTFSGFSLS 70 WIRQPPGKALEWLA 71
RLTISKDTSKNQVVLTMTNMDPVDTATYYCAR 72 WGQGTTVTVSS 73
EVTLKESGPVLVKPTETLTLTCTVSGFSLS 74 WIRQPPGKALEWLA 75
RLTISKDTSKSQVVLTMTNMDPVDTATYYCAR 76 WGQGTTVTVSS 77
EVQLVESGGGLVQPGGSLRLSCAASGFTFS 78 WVRQAPGKGLEWVG 79
RFTISRDDSKNSLYLQMNSLKTEDTAVYYCAR 80 WGQGTTVTVSS 81
EVQLVESGGGLVKPGGSLRLSCAASGFTFS 82 WVRQAPGKGLEWVS 83
RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR 84 WGQGTTVTVSS 85
EVQLVQSGAEVKKPGSSVKVSCKASGGTFS 86 WVRQAPGQGLEWMG 87
RVTITADKSTSTAYMELSSLRSEDTAVYYCAR 88 WGQGTTVTVSS 89
EVQLVQSGAEVKKPGASVKVS CKASGYTFT 90 WVRQAPGQGLEWMG 91
RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR 92 WGQGTTVTVSS
TABLE-US-00005 TABLE 5 LIGHT CHAIN DONOR SEQUENCES FOR TnI 19C7 AM1
Sequence SEQ ID No. 12345678901234567890123456789012 93
DIVMTQSPDSLAVSLGERATINC 94 WYQQKPGQPPKLLIY 95
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC 96 FGGGTKVEIKR 97
EIVMTQSPATLSVSPGERATLSC 98 WYQQKPGQAPRLLIY 99
GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC 100 FGGGTKVEIKR 101
DIQMTQSPSSLSASVGDRVTITC 102 WYQQKPEKAPKSLIY 103
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC 104 FGGGTKVEIKR 105
DIQMTQSPSSVSASVGDRVTITC 106 WYQOKPGKAPKLLIY 107
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC 108 FGGGTKVEIKR
As used herein, the term "germline antibody gene" or "gene
fragment" refers to an immunoglobulin sequence encoded by
non-lymphoid cells that have not undergone the maturation process
that leads to genetic rearrangement and mutation for expression of
a particular immunoglobulin. (See, e.g., Shapiro et al., Crit. Rev.
Immunol. 22(3): 183-200 (2002); Marchalonis et al., Adv Exp Med
Biol. 484:13-30 (2001)). One of the advantages provided by various
embodiments of the present invention stems from the recognition
that germline antibody genes are more likely than mature antibody
genes to conserve essential amino acid sequence structures
characteristic of individuals in the species, hence less likely to
be recognized as from a foreign source when used therapeutically in
that species.
As used herein, the term "key" residues refer to certain residues
within the variable region that have more impact on the binding
specificity and/or affinity of an antibody, in particular a
humanized antibody. A key residue includes, but is not limited to,
one or more of the following: a residue that is adjacent to a CDR,
a potential glycosylation site (can be either N- or O-glycosylation
site), a rare residue, a residue capable of interacting with the
antigen, a residue capable of interacting with a CDR, a canonical
residue, a contact residue between heavy chain variable region and
light chain variable region, a residue within the Vernier zone, and
a residue in the region that overlaps between the Chothia
definition of a variable heavy chain CDR1 and the Kabat definition
of the first heavy chain framework.
As used herein, the term "humanized antibody" is an antibody or a
variant, derivative, analog or fragment thereof which
immunospecifically binds to an antigen of interest and which
comprises a framework (FR) region having substantially the amino
acid sequence of a human antibody and a complementary determining
region (CDR) having substantially the amino acid sequence of a
non-human antibody. As used herein, the term "substantially" in the
context of a CDR refers to a CDR having an amino acid sequence at
least 80%, preferably at least 85%, more preferably at least 90%,
more preferably at least 95%, more preferably at least 98% and most
preferably at least 99% identical to the amino acid sequence of a
non-human antibody CDR. A humanized antibody comprises
substantially all of at least one, and typically two, variable
domains (Fab, Fab', F(ab')2, FabC, Fv) in which all or
substantially all of the CDR regions correspond to those of a
non-human immunoglobulin (i.e., donor antibody) and all or
substantially all of the framework regions are those of a human
immunoglobulin consensus sequence. Preferably, a humanized antibody
also comprises at least a portion of an immunoglobulin constant
region (Fc), typically that of a human immunoglobulin. In some
embodiments, a humanized antibody contains both the light chain as
well as at least the variable domain of a heavy chain. The antibody
also may include the CH1, hinge, CH2, CH3, and CH4 regions of the
heavy chain. In other embodiments, a humanized antibody only
contains a humanized light chain. In some embodiments, a humanized
antibody only contains a humanized heavy chain. In specific
embodiments, a humanized antibody only contains a humanized
variable domain of a light chain and/or humanized heavy chain.
The humanized antibody can be selected from any class of
immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any
isotype, including without limitation IgG 1, IgG2, IgG3 and IgG4.
The humanized antibody may comprise sequences from more than one
class or isotype, and particular constant domains may be selected
to optimize desired effector functions using techniques well-known
in the art.
The framework and CDR regions of a humanized antibody need not
correspond precisely to the parental sequences, e.g., the donor
antibody CDR or the consensus framework may be mutagenized by
substitution, insertion and/or deletion of at least one amino acid
residue so that the CDR or framework residue at that site does not
correspond to either the donor antibody or the consensus framework.
In a preferred embodiment, such mutations, however, will not be
extensive. Usually, at least 80%, preferably at least 85%, more
preferably at least 90%, and most preferably at least 95% of the
humanized antibody residues will correspond to those of the
parental FR and CDR sequences. As used herein, the term "consensus
framework" refers to the framework region in the consensus
immunoglobulin sequence. As used herein, the term "consensus
immunoglobulin sequence" refers to the sequence formed from the
most frequently occurring amino acids (or nucleotides) in a family
of related immunoglobulin sequences (See e.g., Winnaker, From Genes
to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a
family of immunoglobulins, each position in the consensus sequence
is occupied by the amino acid occurring most frequently at that
position in the family. If two amino acids occur equally
frequently, either can be included in the consensus sequence.
As used herein, "Vernier" zone refers to a subset of framework
residues that may adjust CDR structure and fine-tune the fit to
antigen as described by Foote and Winter (1992, J. Mol. Biol.
224:487-499, which is incorporated herein by reference). Vernier
zone residues form a layer underlying the CDRs and may impact on
the structure of CDRs and the affinity of the antibody.
The term "activity" includes activities such as the binding
specificity/affinity of an antibody for an antigen, for example, an
anti-troponin I antibody that binds to troponin I.
The term "epitope" includes any polypeptide determinant capable of
specific binding to an immunoglobulin or T-cell receptor. In
certain embodiments, epitope determinants include chemically active
surface groupings of molecules such as amino acids, sugar side
chains, phosphoryl, or sulfonyl and, in certain embodiments, may
have specific three-dimensional structural characteristics, and/or
specific charge characteristics. An epitope is a region of an
antigen that is bound by an antibody. In certain embodiments, an
antibody is said to specifically bind an antigen when it
preferentially recognizes its target antigen in a complex mixture
of proteins and/or macromolecules.
The term "surface plasmon resonance", as used herein, refers to an
optical phenomenon that allows for the analysis of real-time
biospecific interactions by detection of alterations in protein
concentrations within a biosensor matrix, for example using the
BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and
Piscataway, N.J.). For further descriptions, see Jonsson, U., et
al. (1993) Ann. Biol. Clin. 51:19-26; Jonsson, U., et al. (1991)
Biotechniques 11:620-627; Johnsson, B., et al. (1995) J. Mol.
Recognit. 8:125-131; and Johnnson, B., et al. (1991) Anal. Biochem.
198:268-277.
The term "K.sub.on", as used herein, is intended to refer to the on
rate constant for association of an antibody to the antigen to form
the antibody/antigen complex as is known in the art.
The term "K.sub.off", as used herein, is intended to refer to the
off rate constant for dissociation of an antibody from the
antibody/antigen complex as is known in the art.
The term "K.sub.d" or "K.sub.D", as used herein, is intended to
refer to the dissociation constant of a particular antibody-antigen
interaction as is known in the art.
The term "labeled binding protein" as used herein, refers to a
protein with a label incorporated that provides for the
identification of the binding protein. Preferably, the label is a
detectable marker, e.g., incorporation of a radiolabeled amino acid
or attachment to a polypeptide of biotinyl moieties that can be
detected by marked avidin (e.g., streptavidin containing a
fluorescent marker or enzymatic activity that can be detected by
optical or calorimetric methods). Examples of labels for
polypeptides include, but are not limited to, the following:
radioisotopes or radionuclides (e.g., .sup.3H, .sup.14C, .sup.35S,
.sup.90Y, .sup.99Tc, .sup.111In, .sup.125I, .sup.131I, .sup.177Lu,
.sup.166Ho, or .sup.153Sm); fluorescent labels (e.g., FITC,
rhodamine, lanthanide phosphors), enzymatic labels (e.g.,
horseradish peroxidase, luciferase, alkaline phosphatase);
chemiluminescent markers; biotinyl groups; predetermined
polypeptide epitopes recognized by a secondary reporter (e.g.,
leucine zipper pair sequences, binding sites for secondary
antibodies, metal binding domains, epitope tags); and magnetic
agents, such as gadolinium chelates.
The term "antibody conjugate" refers to a binding protein, such as
an antibody, chemically linked to a second chemical moiety, such as
a therapeutic or cytotoxic agent. The term "agent" is used herein
to denote a chemical compound, a mixture of chemical compounds, a
biological macromolecule, or an extract made from biological
materials. Preferably the therapeutic or cytotoxic agents include,
but are not limited to, pertussis toxin, taxol, cytochalasin B,
gramicidin D, ethidium bromide, emetine, mitomycin, etoposide,
tenoposide, vincristine, vinblastine, colchicin, doxorubicin,
daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin,
actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine,
tetracaine, lidocaine, propranolol, and puromycin and analogs or
homologs thereof. The terms "crystal", and "crystallized" as used
herein, refer to an antibody, or antigen-binding portion thereof,
that exists in the form of a crystal. Crystals are one form of the
solid state of matter, which is distinct from other forms such as
the amorphous solid state or the liquid crystalline state. Crystals
are composed of regular, repeating, three-dimensional arrays of
atoms, ions, molecules (e.g., proteins such as antibodies), or
molecular assemblies (e.g., antigen/antibody complexes). These
three-dimensional arrays are arranged according to specific
mathematical relationships that are well-understood in the field.
The fundamental unit, or building block, that is repeated in a
crystal is called the asymmetric unit. Repetition of the asymmetric
unit in an arrangement that conforms to a given, well-defined
crystallographic symmetry provides the "unit cell" of the crystal.
Repetition of the unit cell by regular translations in all three
dimensions provides the crystal. See Giege, R. and Ducruix, A.
Barrett, Crystallization of Nucleic Acids and Proteins, a Practical
Approach, 2nd ed., pp. 20 1-16, Oxford University Press, New York,
N.Y., (1999)."
The term "polynucleotide" as referred to herein means a polymeric
form of two or more nucleotides, either ribonucleotides or
deoxynucleotides or a modified form of either type of nucleotide.
The term includes single and double-stranded forms of DNA but
preferably is double-stranded DNA.
The term "isolated polynucleotide" as used herein shall mean a
polynucleotide (e.g., of genomic, cDNA, or synthetic origin, or
some combination thereof) that, by virtue of its origin, is not
associated with all or a portion of a polynucleotide with which the
"isolated polynucleotide" is found in nature; is operably linked to
a polynucleotide that it is not linked to in nature; or does not
occur in nature as part of a larger sequence.
The term "vector", as used herein, is intended to refer to a
nucleic acid molecule capable of transporting another nucleic acid
to which it has been linked. One type of vector is a "plasmid",
which refers to a circular double stranded DNA loop into which
additional DNA segments may be ligated. Another type of vector is a
viral vector, wherein additional DNA segments may be ligated into
the viral genome. Certain vectors are capable of autonomous
replication in a host cell into which they are introduced (e.g.,
bacterial vectors having a bacterial origin of replication and
episomal mammalian vectors). Other vectors (e.g., non-episomal
mammalian vectors) can be integrated into the genome of a host cell
upon introduction into the host cell, and thereby are replicated
along with the host genome. Moreover, certain vectors are capable
of directing the expression of genes to which they are operatively
linked. Such vectors are referred to herein as "recombinant
expression vectors" (or simply, "expression vectors"). In general,
expression vectors of utility in recombinant DNA techniques are
often in the form of plasmids. In the present specification,
"plasmid" and "vector" may be used interchangeably as the plasmid
is the most commonly used form of vector. However, the invention is
intended to include such other forms of expression vectors, such as
viral vectors (e.g., replication defective retroviruses,
adenoviruses and adeno-associated viruses), which serve equivalent
functions.
The term "operably linked" refers to a juxtaposition wherein the
components described are in a relationship permitting them to
function in their intended manner. A control sequence "operably
linked" to a coding sequence is ligated in such a way that
expression of the coding sequence is achieved under conditions
compatible with the control sequences. "Operably linked" sequences
include both expression control sequences that are contiguous with
the gene of interest and expression control sequences that act in
trans or at a distance to control the gene of interest. The term
"expression control sequence" as used herein refers to
polynucleotide sequences that are necessary to effect the
expression and processing of coding sequences to which they are
ligated. Expression control sequences include appropriate
transcription initiation, termination, promoter and enhancer
sequences; efficient RNA processing signals such as splicing and
polyadenylation signals; sequences that stabilize cytoplasmic mRNA;
sequences that enhance translation efficiency (i.e., Kozak
consensus sequence); sequences that enhance protein stability; and
when desired, sequences that enhance protein secretion. The nature
of such control sequences differs depending upon the host organism;
in prokaryotes, such control sequences generally include promoter,
ribosomal binding site, and transcription termination sequence; in
eukaryotes, generally, such control sequences include promoters and
transcription termination sequence. The term "control sequences" is
intended to include components whose presence is essential for
expression and processing, and can also include additional
components whose presence is advantageous, for example, leader
sequences and fusion partner sequences.
"Transformation", as defined herein, refers to any process by which
exogenous DNA enters a host cell. Transformation may occur under
natural or artificial conditions using various methods well known
in the art. Transformation may rely on any known method for the
insertion of foreign nucleic acid sequences into a prokaryotic or
eukaryotic host cell. The method is selected based on the host cell
being transformed and may include, but is not limited to, viral
infection, electroporation, lipofection, and particle bombardment.
Such "transformed" cells include stably transformed cells in which
the inserted DNA is capable of replication either as an
autonomously replicating plasmid or as part of the host chromosome.
They also include cells that transiently express the inserted DNA
or RNA for limited periods of time.
The term "recombinant host cell" (or simply "host cell"), as used
herein, is intended to refer to a cell into which exogenous DNA has
been introduced. It should be understood that such terms are
intended to refer not only to the particular subject cell but also
to the progeny of such a cell. Because certain modifications may
occur in succeeding generations due to either mutation or
environmental influences, such progeny may not, in fact, be
identical to the parent cell, but are still included within the
scope of the term "host cell" as used herein. Preferably host cells
include prokaryotic and eukaryotic cells selected from any of the
Kingdoms of life. Preferred eukaryotic cells include protist,
fungal, plant and animal cells. Most preferably host cells include
but are not limited to the prokaryotic cell line E. coli; mammalian
cell lines CHO, HEK 293 and COS; the insect cell line Sf9; and the
fungal cell Saccharomyces cerevisiae or Picchia pastoris.
Standard techniques may be used for recombinant DNA,
oligonucleotide synthesis, and tissue culture and transformation
(e.g., electroporation, lipofection). Enzymatic reactions and
purification techniques may be performed according to
manufacturer's specifications or as commonly accomplished in the
art or as described herein. The foregoing techniques and procedures
may be generally performed according to conventional methods well
known in the art and as described in various general and more
specific references that are cited and discussed throughout the
present specification. See e.g., Sambrook et al. Molecular Cloning:
A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by
reference for any purpose.
"Transgenic organism", as known in the art and as used herein,
refers to an organism having cells that contain a transgene,
wherein the transgene introduced into the organism (or an ancestor
of the organism) expresses a polypeptide not naturally expressed in
the organism. A "transgene" is a DNA construct, which is stably and
operably integrated into the genome of a cell from which a
transgenic organism develops, directing the expression of an
encoded gene product in one or more cell types or tissues of the
transgenic organism.
The term "regulate" and "modulate" are used interchangeably, and,
as used herein, refers to a change or an alteration in the activity
of a molecule of interest (e.g., the biological activity of
troponin I). Modulation may be an increase or a decrease in the
magnitude of a certain activity or function of the molecule of
interest. Exemplary activities and functions of a molecule include,
but are not limited to, binding characteristics, enzymatic
activity, cell receptor activation, and signal transduction.
Correspondingly, the term "modulator," as used herein, is a
compound capable of changing or altering an activity or function of
a molecule of interest (e.g., the biological activity of troponin
I). For example, a modulator may cause an increase or decrease in
the magnitude of a certain activity or function of a molecule
compared to the magnitude of the activity or function observed in
the absence of the modulator. In certain embodiments, a modulator
is an inhibitor, which decreases the magnitude of at least one
activity or function of a molecule. Exemplary inhibitors include,
but are not limited to, proteins, peptides, antibodies,
peptibodies, carbohydrates or small organic molecules. Peptibodies
are described, e.g., in International Application Publication No.
WO 01/83525.
The term "agonist", as used herein, refers to a modulator that,
when contacted with a molecule of interest, causes an increase in
the magnitude of a certain activity or function of the molecule
compared to the magnitude of the activity or function observed in
the absence of the agonist. Particular agonists of interest may
include, but are not limited to, troponin I polypeptides, nucleic
acids, carbohydrates, or any other molecules that bind to troponin
I.
The term "antagonist" or "inhibitor", as used herein, refer to a
modulator that, when contacted with a molecule of interest causes a
decrease in the magnitude of a certain activity or function of the
molecule compared to the magnitude of the activity or function
observed in the absence of the antagonist.
As used herein, the term "effective amount" refers to the amount of
a therapy which is sufficient to reduce or ameliorate the severity
and/or duration of a disorder or one or more symptoms thereof,
prevent the advancement of a disorder, cause regression of a
disorder, prevent the recurrence, development, onset or progression
of one or more symptoms associated with a disorder, detect a
disorder, or enhance or improve the prophylactic or therapeutic
effect(s) of another therapy (e.g., prophylactic or therapeutic
agent).
The term "sample", as used herein, is used in its broadest sense. A
"biological sample", as used herein, includes, but is not limited
to, any quantity of a substance from a living thing or formerly
living thing. Such living things include, but are not limited to,
humans, mice, rats, monkeys, dogs, rabbits and other mammalian or
non-mammalian animals. Such substances include, but are not limited
to, blood, serum, urine, synovial fluid, cells, organs, tissues
(e.g., brain), bone marrow, lymph nodes, cerebrospinal fluid, and
spleen.
Methods of Making Antibodies
Antibodies of the present invention may be made by any of a number
of techniques known in the art. For example, antibodies can be
prepared using a wide variety of techniques including the use of
recombinant or phage display technologies, or a combination
thereof. The term "monoclonal antibody" refers to an antibody that
is derived from a single clone, including any eukaryotic,
prokaryotic, or phage clone, and not the method by which it is
produced.
In one embodiment, the present invention provides a method of
generating recombinant antibodies (as well as antibodies produced
by the method) comprising culturing a Chinese Hamster Ovary cell
line secreting an antibody of the invention.
Further, fragments of the antibody of the present invention which
recognize specific epitopes may be generated by known techniques.
For example, Fab and F(ab')2 fragments of the invention may be
produced by proteolytic cleavage of immunoglobulin molecules, using
enzymes such as papain (to produce Fab fragments) or pepsin (to
produce F(ab')2 fragments). F(ab')2 fragments contain the variable
region, the light chain constant region and the CHI domain of the
heavy chain.
Production of Anti-Troponin I Antibodies Using Recombinant Antibody
Libraries
In vitro methods also can be used to make the antibodies of the
invention, wherein an antibody library is screened to identify an
antibody having the desired binding specificity. Methods for such
screening of recombinant antibody libraries are well known in the
art and include methods described in, for example, Ladner et al.,
U.S. Pat. No. 5,223,409; Kang et al., International Appln.
Publication No. WO 92/18619; Dower et al., International Appln.
Publication No. WO 91/17271; Winter et al., International Appln.
Publication No. WO 92/20791; Markland et al., International Appln.
Publication No. WO 92/15679; Breitling et al., International Appln.
Publication No. WO 93/01288; McCafferty et al., PCT Publication No.
WO 92/01047; Garrard et al., International Appln. Publication No.
WO 92/09690; Fuchs et al. (1991), Bio/Technology 9:1370-1372; Hay
et al., (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989),
Science 246: 1275-1281; McCafferty et al., Nature (1990)
348:552-554; Griffiths et al. (1993) EMBO J 12:725-734; Hawkins et
al., (1992) J Mol Biol 226:889-896; Clackson et al., (1991) Nature
352:624-628; Gram et al., (1992) PNAS 89:3576-3580; Garrad et al.
(1991) Bio/Technology 9:1373-1377; Hoogenboom et al. (1991), Nuc
Acid Res 19:4133-4137; and Barbas et al. (1991), PNAS 88:7978-7982,
U.S. Patent Application Publication No. 20030186374, and
International Application Publication No. WO 97/29131, the contents
of each of which are incorporated herein by reference.
The recombinant antibody library may be from a subject immunized
with troponin I, or a portion thereof Alternatively, the
recombinant antibody library may be from a naive subject, i.e., one
who has not been immunized with troponin I, such as a human
antibody library from a human subject who has not been immunized
with human troponin I. Antibodies of the invention are selected by
screening the recombinant antibody library with the peptide
comprising human troponin I to thereby select those antibodies that
recognize troponin I. Methods for conducting such screening and
selection are well known in the art, such as described in the
references in the preceding paragraph. To select antibodies of the
invention having particular binding affinities for troponin I, such
as those that dissociate from human troponin I with a particular
k.sub.off rate constant, the art-known method of surface plasmon
resonance can be used to select antibodies having the desired
k.sub.off rate constant.
In one aspect, the invention pertains to an isolated antibody, or
an antigen-binding portion thereof, that binds human troponin I. In
various embodiments, the antibody is a recombinant antibody.
In another approach the antibodies of the present invention can
also be generated using yeast display methods known in the art. In
yeast display methods, genetic methods are used to tether antibody
domains to the yeast cell wall and display them on the surface of
yeast. In particular, such yeast can be utilized to display
antigen-binding domains expressed from a repertoire or
combinatorial antibody library (e.g., human or murine). Examples of
yeast display methods that can be used to make the antibodies of
the present invention include those disclosed Wittrup et al., U.S.
Pat. No. 6,699,658 incorporated herein by reference.
Production of Recombinant Antibodies
As noted above, antibodies of the present invention may be produced
by any number of techniques known in the art. For example,
expression from host cells, wherein expression vector(s) encoding
the heavy and light chains is (are) transfected into a host cell by
standard techniques is the preferred method of producing the
antibodies of the present invention. (The various forms of the term
"transfection" are intended to encompass a wide variety of
techniques commonly used for the introduction of exogenous DNA into
a prokaryotic or eukaryotic host cell, e.g., electroporation,
calcium-phosphate precipitation, DEAE-dextran transfection and the
like.) Although it is possible to express the antibodies of the
invention in either prokaryotic or eukaryotic host cells,
expression of antibodies in eukaryotic cells is preferable, and
most preferable in mammalian host cells, because such eukaryotic
cells (and in particular mammalian cells) are more likely than
prokaryotic cells to assemble and secrete a properly folded and
immunologically active antibody.
Preferred mammalian host cells for expressing the recombinant
antibodies of the invention include Chinese Hamster Ovary (CHO
cells) (including dhfr--CHO cells, described in Urlaub and Chasin,
(1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR
selectable marker, e.g., as described in R. J. Kaufman and P. A.
Sharp (1982) Mol. Biol. 159:601-621), NS0 myeloma cells, COS cells
and SP2 cells. When recombinant expression vectors encoding
antibody genes are introduced into mammalian host cells, the
antibodies are produced by culturing the host cells for a period of
time sufficient to allow for expression of the antibody in the host
cells or, more preferably, secretion of the antibody into the
culture medium in which the host cells are grown. Antibodies can be
recovered from the culture medium using standard protein
purification methods.
Host cells can also be used to produce functional antibody
fragments, such as Fab fragments or scFv molecules. It will be
understood that variations on the above procedure are within the
scope of the present invention. For example, it may be desirable to
transfect a host cell with DNA encoding functional fragments of
either the light chain and/or the heavy chain of an antibody of
this invention. Recombinant DNA technology may also be used to
remove some, or all, of the DNA encoding either or both of the
light and heavy chains that is not necessary for binding to the
antigens of interest. The molecules expressed from such truncated
DNA molecules are also encompassed by the antibodies of the
invention. In addition, bifunctional antibodies may be produced in
which one heavy and one light chain are an antibody of the
invention and the other heavy and light chain are specific for an
antigen other than the antigens of interest by crosslinking an
antibody of the invention to a second antibody by standard chemical
crosslinking methods.
In a preferred system for recombinant expression of an antibody, or
antigen-binding portion thereof, of the invention, a recombinant
expression vector encoding both the antibody heavy chain and the
antibody light chain is introduced into dhfr--CHO cells by calcium
phosphate-mediated transfection. Within the recombinant expression
vector, the antibody heavy and light chain genes are each
operatively linked to CMV enhancer/AdMLP promoter regulatory
elements to drive high levels of transcription of the genes. The
recombinant expression vector also carries a DHFR gene, which
allows for selection of CHO cells that have been transfected with
the vector using methotrexate selection/amplification. The selected
transformant host cells are cultured to allow for expression of the
antibody heavy and light chains and intact antibody is recovered
from the culture medium. Standard molecular biology techniques are
used to prepare the recombinant expression vector, transfect the
host cells, select for transformants, culture the host cells and
recover the antibody from the culture medium. Still further the
invention provides a method of synthesizing a recombinant antibody
of the invention by culturing a host cell of the invention in a
suitable culture medium until a recombinant antibody of the
invention is synthesized. The method can further comprise isolating
the recombinant antibody from the culture medium.
Anti-Troponin Antibodies
The isolated anti-troponin I antibody CDR sequences described
herein (see Tables 1 and 2) establish a novel family of troponin I
binding proteins, isolated in accordance with this invention, and
comprising polypeptides that include the CDR sequences listed in
Tables 1 and 2 above. To generate and to select CDRs of the
invention having preferred troponin I binding activity, standard
methods known in the art for generating binding proteins of the
present invention and assessing the binding characteristics thereof
may be used, including but not limited to those specifically
described herein.
Anti-Troponin I Chimeric Antibodies
A chimeric antibody is a molecule in which different portions of
the antibody are derived from different animal species, such as
antibodies having a variable region derived from a murine
monoclonal antibody and a human immunoglobulin constant region.
Methods for producing chimeric antibodies, such as those of the
present invention, are well known in the art. See e.g., Morrison,
Science 229:1202 (1985); Oi et al., BioTechniques 4;214 (1986);
Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Pat.
Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated
herein by reference in their entireties. In addition, techniques
developed for the production of "chimeric antibodies" (Morrison et
al., 1984, Proc. Natl. Acad. Sci. 81:851-855; Neuberger et al.,
1984, Nature 312:604-608; Takeda et al., 1985, Nature 314: 452-454
which are incorporated herein by reference in their entireties) by
splicing genes from a mouse antibody molecule of appropriate
antigen specificity together with genes from a human antibody
molecule of appropriate biological activity can be used.
In one embodiment, the chimeric antibodies of the invention are
produced by replacing the heavy chain constant region of the
antibodies described above with a human IgG1 constant region. In a
specific embodiment, the chimeric antibody of the invention
comprises a heavy chain variable region (V.sub.H) comprising the
amino acid sequence of SEQ ID NO:25 and a light chain variable
region (V.sub.L) comprising the amino acid sequence of SEQ ID
NO:28.
Anti-Troponin I CDR Grafted Antibodies
CDR-grafted antibodies of the invention comprise heavy and light
chain variable region sequences from a human antibody wherein one
or more of the CDR regions of V.sub.H and/or V.sub.L are replaced
with CDR sequences of the murine antibodies of the invention. A
framework sequence from any human antibody may serve as the
template for CDR grafting. However, straight chain replacement onto
such a framework often leads to some loss of binding affinity to
the antigen. The more homologous a human antibody is to the
original murine antibody, the less likely the possibility that
combining the murine CDRs with the human framework will introduce
distortions in the CDRs that could reduce affinity. Therefore, it
is preferable that the human variable framework that is chosen to
replace the murine variable framework apart from the CDRs have at
least a 65% sequence identity with the murine antibody variable
region framework. It is more preferable that the human and murine
variable regions apart from the CDRs have at least 70% sequence
identify. It is even more preferable that the human and murine
variable regions apart from the CDRs have at least 75% sequence
identity. It is most preferable that the human and murine variable
regions apart from the CDRs have at least 80% sequence identity.
Methods for producing chimeric antibodies are known in the art and
discussed in detail in Example 2.2. (See also EP 239,400; Intern.
Appln. Publication No. WO 91/09967; U.S. Pat. Nos. 5,225,539;
5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP
519,596; Padlan, Molecular Immunology 28(4/5): 489-498 (1991);
Studnicka et al., Protein Engineering 7(6): 805-814 (1994); Roguska
et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Pat. No.
5,565,352).
Humanized Antibodies
Humanized antibodies are antibody molecules from non-human species
antibody that bind the desired antigen having one or more
complementarity determining regions (CDRs) from the non-human
species and framework regions from a human immunoglobulin molecule
Such imported sequences can be used to reduce immunogenicity or
reduce, enhance or modify binding, affinity, on-rate, off-rate,
avidity, specificity, half-life, or any other suitable
characteristic, as known in the art.
Framework residues in the human framework regions may be
substituted with the corresponding residue from the CDR donor
antibody to alter, preferably improve, antigen binding. These
framework substitutions are identified by methods well known in the
art, e.g., by modeling of the interactions of the CDR and framework
residues to identify framework residues important for antigen
binding and sequence comparison to identify unusual framework
residues at particular positions. (See, e.g., Queen et al., U.S.
Pat. No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which
are incorporated herein by reference in their entireties.)
Three-dimensional immunoglobulin models are commonly available and
are familiar to those skilled in the art. Computer programs are
available which illustrate and display probable three-dimensional
conformational structures of selected candidate immunoglobulin
sequences. Inspection of these displays permits analysis of the
likely role of the residues in the functioning of the candidate
immunoglobulin sequence, i.e., the analysis of residues that
influence the ability of the candidate immunoglobulin to bind its
antigen. In this way, FR residues can be selected and combined from
the consensus and import sequences so that the desired antibody
characteristic, such as increased affinity for the target
antigen(s), is achieved. In general, the CDR residues are directly
and most substantially involved in influencing antigen binding.
Antibodies can be humanized using a variety of techniques known in
the art, such as but not limited to those described in Jones et
al., Nature 321:522 (1986); Verhoeyen et al., Science 239:1534
(1988)), Sims et al., J. Immunol. 151: 2296 (1993); Chothia and
Lesk, J. Mol. Biol. 196:901 (1987), Carter et al., Proc. Natl.
Acad. Sci. U.S.A. 89:4285 (1992); Presta et al., J. Immunol.
151:2623 (1993), Padlan, Molecular Immunology 28(4/5):489-498
(1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994);
Roguska et al., PNAS 91:969-973 (1994); International Appln.
Publication No. WO 91/09967, PCT/: US98/16280, US96/18978,
US91/09630, US91/05939, US94/01234, GB89/01334, GB91/01134,
GB92/01755; WO90/14443, WO90/14424, WO90/14430, EP 229246, EP
592,106; EP 519,596, EP 239,400, U.S. Pat. Nos. 5,565,332,
5,723,323, 5,976,862, 5,824,514, 5,817,483, 5,814,476, 5,763,192,
5,723,323, 5,766,886, 5,714,352, 6,204,023, 6,180,370, 5,693,762,
5,530,101, 5,585,089, 5,225,539; 4,816,567, each entirely
incorporated herein by reference, included references cited
therein.
Production of Antibodies and Antibody-Producing Cell Lines
As noted above, preferably, antibodies of the present invention
exhibit a high capacity to bind specifically to troponin I, e.g.,
as assessed by any one of several in vitro and in vivo assays known
in the art (e.g., see examples below).
In certain embodiments, the antibody comprises a heavy chain
constant region, such as an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM
or IgD constant region. Preferably, the heavy chain constant region
is an IgG1 heavy chain constant region or an IgG4 heavy chain
constant region. Furthermore, the antibody can comprise a light
chain constant region, either a kappa light chain constant region
or a lambda light chain constant region. Preferably, the antibody
comprises a kappa light chain constant region. Alternatively, the
antibody portion can be, for example, a Fab fragment or a single
chain Fv fragment.
Replacements of amino acid residues in the Fc portion to alter
antibody effector function are known in the art (Winter et al.,
U.S. Pat. Nos. 5,648,260 and 5,624,821). The Fc portion of an
antibody mediates several important effector functions, for
example, cytokine induction, ADCC, phagocytosis, complement
dependent cytotoxicity (CDC) and half-life/clearance rate of
antibody- and antigen-antibody complexes. In some cases these
effector functions are desirable for therapeutic antibody but in
other cases might be unnecessary or even deleterious, depending on
the therapeutic objectives. Certain human IgG isotypes,
particularly IgG1 and IgG3, mediate ADCC and CDC via binding to
Fc.gamma.Rs and complement Clq, respectively. Neonatal Fc receptors
(FcRn) are the critical components determining the circulating
half-life of antibodies. In still another embodiment, at least one
amino acid residue is replaced in the constant region of the
antibody, for example the Fc region of the antibody, such that
effector functions of the antibody are altered.
One embodiment provides a labeled binding protein wherein an
antibody or antibody portion of the invention is derivatized or
linked to another functional molecule (e.g., another peptide or
protein). For example, a labeled binding protein of the invention
can be derived by functionally linking an antibody or antibody
portion of the invention (by chemical coupling, genetic fusion,
noncovalent association or otherwise) to one or more other
molecular entities, such as another antibody (e.g., a bispecific
antibody or a diabody), a detectable agent, a cytotoxic agent, a
pharmaceutical agent, and/or a protein or peptide that can mediate
associate of the antibody or antibody portion with another molecule
(such as a streptavidin core region or a polyhistidine tag).
Useful detectable agents with which an antibody or antibody portion
of the invention may be derivatized include fluorescent compounds.
Exemplary fluorescent detectable agents include fluorescein,
fluorescein isothiocyanate, rhodamine,
5-dimethylamine-1-napthalenesulfonyl chloride, phycoerythrin and
the like. An antibody may also be derivatized with detectable
enzymes, such as alkaline phosphatase, horseradish peroxidase,
glucose oxidase and the like. When an antibody is derivatized with
a detectable enzyme, it is detected by adding additional reagents
that the enzyme uses to produce a detectable reaction product. For
example, when the detectable agent horseradish peroxidase is
present, the addition of hydrogen peroxide and diaminobenzidine
leads to a colored reaction product, which is detectable. An
antibody may also be derivatized with biotin, and detected through
indirect measurement of avidin or streptavidin binding.
Another embodiment of the invention provides a crystallized binding
protein. Preferably, the invention relates to crystals of whole
anti-troponin I antibodies and fragments thereof as disclosed
herein, and formulations and compositions comprising such crystals.
In one embodiment the crystallized binding protein has a greater
half-life in vivo than the soluble counterpart of the binding
protein. In another embodiment, the binding protein-retains
biological activity after crystallization.
Crystallized binding protein of the invention may be produced
according methods known in the art and as disclosed in
International Appln. Publication No. WO 02/072636, incorporated
herein by reference.
Another embodiment of the invention provides a glycosylated binding
protein wherein the antibody or antigen-binding portion thereof
comprises one or more carbohydrate residues. Nascent in vivo
protein production may undergo further processing, known as
post-translational modification. In particular, sugar (glycosyl)
residues may be added enzymatically, a process known as
glycosylation. The resulting proteins bearing covalently linked
oligosaccharide side chains are known as glycosylated proteins or
glycoproteins. Antibodies are glycoproteins with one or more
carbohydrate residues in the Fc domain, as well as the variable
domain. Carbohydrate residues in the Fc domain have important
effect on the effector function of the Fc domain, with minimal
effect on antigen binding or half-life of the antibody (R.
Jefferis, Biotechnol. Prog. 21 (2005), pp. 11-16). In contrast,
glycosylation of the variable domain may have an effect on the
antigen binding activity of the antibody. Glycosylation in the
variable domain may have a negative effect on antibody binding
affinity, likely due to steric hindrance (Co, M. S., et al., Mol.
Immunol. (1993) 30:1361-1367), or result in increased affinity for
the antigen (Wallick, S. C., et al., Exp. Med. (1988)
168:1099-1109; Wright, A., et al., EMBO J. (1991) 10:2717
2723).
One aspect of the present invention is directed to generating
glycosylation site mutants in which the O- or N-linked
glycosylation site of the binding protein has been mutated. One
skilled in the art can generate such mutants using standard
well-known technologies. The creation of glycosylation site mutants
that retain the biological activity but have increased or decreased
binding activity are another object of the present invention.
In still another embodiment, the glycosylation of the antibody or
antigen-binding portion of the invention is modified. For example,
an aglycoslated antibody can be made (i.e., the antibody lacks
glycosylation). Glycosylation can be altered to, for example,
increase the affinity of the antibody for antigen. Such
carbohydrate modifications can be accomplished by, for example,
altering one or more sites of glycosylation within the antibody
sequence. For example, one or more amino acid substitutions can be
made that result in elimination of one or more variable region
glycosylation sites to thereby eliminate glycosylation at that
site. Such aglycosylation may increase the affinity of the antibody
for antigen. Such an approach is described in further detail in
International Appln. Publication No. WO 03/016466A2, and U.S. Pat.
Nos. 5,714,350 and 6,350,861, each of which is incorporated herein
by reference in its entirety.
Additionally or alternatively, a modified antibody of the invention
can be made that has an altered type of glycosylation, such as a
hypofucosylated antibody having reduced amounts of fucosyl residues
or an antibody having increased bisecting GlcNAc structures. Such
altered glycosylation patterns have been demonstrated to increase
the ADCC ability of antibodies. Such carbohydrate modifications can
be accomplished by, for example, expressing the antibody in a host
cell with altered glycosylation machinery. Cells with altered
glycosylation machinery have been described in the art and can be
used as host cells in which to express recombinant antibodies of
the invention to thereby produce an antibody with altered
glycosylation. See, for example, Shields, R. L. et al. (2002) J.
Biol. Chem. 277:26733-26740; Umana et al. (1999) Nat. Biotech.
17:176-1, as well as, European Patent No: EP 1,176,195;
International Appln. Publication Nos. WO 03/035835 and WO
99/5434280, each of which is incorporated herein by reference in
its entirety.
Protein glycosylation depends on the amino acid sequence of the
protein of interest, as well as the host cell in which the protein
is expressed. Different organisms may produce different
glycosylation enzymes (e.g., glycosyltransferases and
glycosidases), and have different substrates (nucleotide sugars)
available. Due to such factors, protein glycosylation pattern, and
composition of glycosyl residues, may differ depending on the host
system in which the particular protein is expressed. Glycosyl
residues useful in the invention may include, but are not limited
to, glucose, galactose, mannose, fucose, n-acetylglucosamine and
sialic acid. Preferably the glycosylated binding protein comprises
glycosyl residues such that the glycosylation pattern is human.
It is known to those skilled in the art that differing protein
glycosylation may result in differing protein characteristics. For
instance, the efficacy of a therapeutic protein produced in a
microorganism host, such as yeast, and glycosylated utilizing the
yeast endogenous pathway may be reduced compared to that of the
same protein expressed in a mammalian cell, such as a CHO cell
line. Such glycoproteins may also be immunogenic in humans and show
reduced half-life in vivo after administration. Specific receptors
in humans and other animals may recognize specific glycosyl
residues and promote the rapid clearance of the protein from the
bloodstream. Other adverse effects may include changes in protein
folding, solubility, susceptibility to proteases, trafficking,
transport, compartmentalization, secretion, recognition by other
proteins or factors, antigenicity, or allergenicity. Accordingly, a
practitioner may prefer a therapeutic protein with a specific
composition and pattern of glycosylation, for example glycosylation
composition and pattern identical, or at least similar, to that
produced in human cells or in the species-specific cells of the
intended subject animal.
Expressing glycosylated proteins different from that of a host cell
may be achieved by genetically modifying the host cell to express
heterologous glycosylation enzymes. Using techniques known in the
art a practitioner may generate antibodies or antigen-binding
portions thereof exhibiting human protein glycosylation. For
example, yeast strains have been genetically modified to express
non-naturally occurring glycosylation enzymes such that
glycosylated proteins (glycoproteins) produced in these yeast
strains exhibit protein glycosylation identical to that of animal
cells, especially human cells (U.S. Patent Application Publication
Nos. 20040018590 and 20020137134 and International Appln.
Publication No. WO 05/100584 A2).
The term "multivalent binding protein" is used in this
specification to denote a binding protein comprising two or more
antigen binding sites. The multivalent binding protein is
preferably engineered to have the three or more antigen binding
sites, and is generally not a naturally occurring antibody. The
term "multispecific binding protein" refers to a binding protein
capable of binding two or more related or unrelated targets. Dual
variable domain (DVD) binding proteins as used herein, are binding
proteins that comprise two or more antigen binding sites and are
tetravalent or multivalent binding proteins. Such DVDs may be
monospecific, i.e., capable of binding one antigen or
multispecific, i.e., capable of binding two or more antigens. DVD
binding proteins comprising two heavy chain DVD polypeptides and
two light chain DVD polypeptides are referred to a DVD Ig. Each
half of a DVD Ig comprises a heavy chain DVD polypeptide, and a
light chain DVD polypeptide, and two antigen binding sites. Each
binding site comprises a heavy chain variable domain and a light
chain variable domain with a total of 6 CDRs involved in antigen
binding per antigen binding site. DVD binding proteins and methods
of making DVD binding proteins are disclosed in U.S. patent
application Ser. No. 11/507,050 and incorporated herein by
reference.
One aspect of the invention pertains to a DVD binding protein
comprising binding proteins capable of binding to troponin I.
Preferably, the DVD binding protein is capable of binding troponin
I and a second target. The present invention also encompasses
triple-variable domain (TVD) binding proteins in which the antibody
is capable of binding troponin I as well as two additional targets
(i.e., a second and third target).
In addition to the binding proteins, the present invention is also
directed to an anti-idiotypic (anti-Id) antibody specific for such
binding proteins of the invention. An anti-Id antibody is an
antibody, which recognizes unique determinants generally associated
with the antigen-binding region of another antibody. The anti-Id
can be prepared by immunizing an animal with the binding protein
(e.g., antibody of interest) or a CDR containing region thereof.
The immunized animal will recognize, and respond to the idiotypic
determinants of the immunizing antibody and produce an anti-Id
antibody. The anti-Id antibody may also be used as an "immunogen"
to induce an immune response in yet another animal, producing a
so-called anti-anti-Id antibody.
Further, it will be appreciated by one skilled in the art that a
protein of interest may be expressed using a library of host cells
genetically engineered to express various glycosylation enzymes,
such that member host cells of the library produce the protein of
interest with variant glycosylation patterns. A practitioner may
then select and isolate the protein of interest with particular
novel glycosylation patterns. Preferably, the protein having a
particularly selected novel glycosylation pattern exhibits improved
or altered biological properties.
Diagnostic Uses of Anti-Troponin I Antibodies
Given their ability to bind to troponin I, the anti-troponin I
antibodies, or portions thereof, of the invention can be used to
detect troponin I (e.g., in a biological sample such as serum,
whole blood, CSF, brain tissue or plasma), using a conventional
immunoassay competitive or non-competitive assay such as, for
example, an enzyme linked immunosorbent assay (ELISA), a
radioimmunoassay (RIA), an immunometric assay or tissue
immunohistochemistry. The invention therefore provides a method for
detecting troponin I in a biological sample comprising contacting a
biological sample with an antibody, or antibody portion, of the
invention and detecting either the antibody (or antibody portion)
bound to troponin I or unbound antibody (or antibody portion), to
thereby detect troponin I in the biological sample. The antibody is
directly or indirectly labeled with a detectable substance to
facilitate detection of the bound or unbound antibody. Suitable
detectable substances include various enzymes, prosthetic groups,
fluorescent materials, luminescent materials and radioactive
materials. Examples of suitable enzymes include horseradish
peroxidase, alkaline phosphatase, .beta.-galactosidase, or
acetyl-cholinesterase; examples of suitable prosthetic group
complexes include streptavidin/biotin and avidin/biotin; examples
of suitable fluorescent materials include umbelliferone,
fluorescein, fluorescein isothiocyanate, rhodamine,
dichlorotriazinylamine fluorescein, dansyl chloride or
phycoerythrin; an example of a luminescent material includes
luminol; and examples of suitable radioactive material include
.sup.3H, .sup.14C, .sup.35S, .sup.90Y, .sup.99Tc, .sup.111In,
.sup.125I, .sup.131I, .sup.177Lu, .sup.166Ho, or .sup.153Sm.
As an alternative to labeling the antibody, troponin I can be
assayed in biological fluids by a competition immunoassay utilizing
recombinant troponin I standards labeled with a detectable
substance and an unlabeled anti-troponin I antibody. In this assay,
the biological sample, the labeled recombinant troponin I standards
and the anti-troponin I antibody are combined, and the amount of
labeled recombinant troponin I standard bound to the unlabeled
antibody is determined. The amount of troponin I in the biological
sample is inversely proportional to the amount of labeled
recombinant troponin I standard bound to the anti-troponin I
antibody.
In particular, in one embodiment of the present invention, one or
more of the antibodies of the present invention are coated on a
solid phase (or are in a liquid phase). The test or biological
sample (e.g., serum, plasma, urine, etc.) is then contacted with
the solid phase. If troponin I antigens are present in the sample,
such antigens bind to the antibodies on the solid phase and are
then detected by either a direct or indirect method. The direct
method comprises simply detecting presence of the complex itself
and thus presence of the antigens. It should be noted that one may
use the full antibody or a fragment thereof in connection with the
antibodies coated on the solid phase. (For purposes of the present
invention, a "fragment" or "portion" of an antibody is defined as a
subunit of the antibody which reacts in the same manner,
functionally, as the full antibody with respect to binding
properties.)
As mentioned above, in the indirect method, a conjugate is added to
the bound antigen. The conjugate comprises a second antibody, which
binds to the bound antigen, attached to a signal-generating
compound or label. Should the second antibody bind to the bound
antigen, the signal-generating compound generates a measurable
signal. Such signal then indicates presence of the antigen (i.e.,
troponin I) in the test sample.
Examples of solid phases used in diagnostic immunoassays are porous
and non-porous materials, latex particles, magnetic particles,
microparticles (see U.S. Pat. No. 5,705,330), beads, membranes,
microtiter wells and plastic tubes. The choice of solid phase
material and method of labeling the antigen or antibody present in
the conjugate, if desired, are determined based upon desired assay
format performance characteristics.
As noted above, the conjugate (or indicator reagent) will comprise
an antibody (or perhaps anti-antibody, depending upon the assay),
attached to a signal-generating compound or label. This
signal-generating compound or "label" is itself detectable or may
be reacted with one or more additional compounds to generate a
detectable product. Examples of signal-generating compounds include
chromogens, radioisotopes (e.g., 125I, 131I, 32P, 3H, 35S and 14C),
chemiluminescent compounds (e.g., acridinium), particles (visible
or fluorescent), nucleic acids, complexing agents, or catalysts
such as enzymes (e.g., alkaline phosphatase, acid phosphatase,
horseradish peroxidase, beta-galactosidase and ribonuclease). In
the case of enzyme use (e.g., alkaline phosphatase or horseradish
peroxidase), addition of a chromo-, fluro-, or lumo-genic substrate
results in generation of a detectable signal. Other detection
systems such as time-resolved fluorescence, internal-reflection
fluorescence, amplification (e.g., polymerase chain reaction) and
Raman spectroscopy are also useful.
As noted above, examples of biological fluids which may be tested
by the above immunoassays include plasma, urine, whole blood, dried
whole blood, serum, cerebrospinal fluid, saliva, tears, nasal
washes or aqueous extracts of tissues and cells.
Additionally, it should also be noted that the initial capture
antibody (for detecting troponin I antigens) used in the
immunoassay may be covalently or non-covalently (e.g., ionic,
hydrophobic, etc.) attached to the solid phase. Linking agents for
covalent attachment are known in the art and may be part of the
solid phase or derivatized to it prior to coating.
Further, the assays and kits of the present invention optionally
can be adapted or optimized for point of care assay systems,
including Abbott's Point of Care (i-STAT.TM.) electrochemical
immunoassay system. Immunosensors and methods of manufacturing and
operating them in single-use test devices are described, for
example in U.S. Pat. No. 5,063,081 and published U.S. Patent
Application Nos. 20030170881, 20040018577, 20050054078, and
20060160164 (incorporated by reference herein for their teachings
regarding same).
Of course, any of the exemplary formats herein and any assay or kit
according to the invention can be adapted or optimized for use in
automated and semi-automated systems (including those in which
there is a solid phase comprising a microparticle), as described,
e.g., in U.S. Pat. Nos. 5,089,424 and 5,006,309, and as, e.g.,
commercially marketed by Abbott Laboratories (Abbott Park, Ill.)
including but not limited to Abbott's ARCHITECT.RTM., AXSYM, IMX,
PRISM, and Quantum II platforms, as well as other platforms.
Other assay formats which may be used for purposes of the present
invention include, for example, a rapid test, a Western blot, as
well as the use of paramagnetic particles in, for example, an
ARCHITECT.RTM. assay (see Frank Quinn, The Immunoassay Handbook,
Second edition, edited by David Wild, pages 363-367, 2001, herein
incorporated in its entirety by reference). Such formats are known
to those of ordinary skill in the art.
It should also be noted that the elements of the assays described
above are particularly suitable for use in the form of a kit. The
kit may also comprise one container such as a vial, bottle or
strip. These kits may also contain vials or containers of other
reagents needed for performing the assay, such as washing,
processing and indicator reagents.
Pharmaceutical Compositions
The invention also provides pharmaceutical compositions comprising
an antibody, or antigen-binding portion thereof, of the invention
and a pharmaceutically acceptable carrier. The pharmaceutical
compositions comprising antibodies of the invention are for use in,
but not limited to, diagnosing, detecting, or monitoring a
disorder, in preventing, treating, managing, or ameliorating of a
disorder or one or more symptoms thereof, and/or in research. In a
specific embodiment, a composition comprises one or more antibodies
of the invention. In another embodiment, the pharmaceutical
composition comprises one or more antibodies of the invention and
one or more prophylactic or therapeutic agents other than
antibodies of the invention for treating a disorder in which
troponin I activity is detrimental. Preferably, the prophylactic or
therapeutic agents known to be useful for or having been or
currently being used in the prevention, treatment, management, or
amelioration of a disorder or one or more symptoms thereof. In
accordance with these embodiments, the composition may further
comprise of a carrier, diluent or excipient.
The antibodies and antibody-portions of the invention can be
incorporated into pharmaceutical compositions suitable for
administration to a subject. Typically, the pharmaceutical
composition comprises an antibody or antibody portion of the
invention and a pharmaceutically acceptable carrier. As used
herein, "pharmaceutically acceptable carrier" includes any and all
solvents, dispersion media, coatings, antibacterial and antifungal
agents, isotonic and absorption delaying agents, and the like that
are physiologically compatible. Examples of pharmaceutically
acceptable carriers include one or more of water, saline, phosphate
buffered saline, dextrose, glycerol, ethanol and the like, as well
as combinations thereof. In many cases, it will be preferable to
include isotonic agents, for example, sugars, polyalcohols such as
mannitol, sorbitol, or sodium chloride in the composition.
Pharmaceutically acceptable carriers may further comprise minor
amounts of auxiliary substances such as wetting or emulsifying
agents, preservatives or buffers, which enhance the shelf life or
effectiveness of the antibody or antibody portion.
Various delivery systems are known and can be used to administer
one or more antibodies of the invention or the combination of one
or more antibodies of the invention and a prophylactic agent or
therapeutic agent useful for preventing, managing treating, or
ameliorating a disorder or one or more symptoms thereof, e.g.,
encapsulation in liposomes, microparticles, microcapsules,
recombinant cells capable of expressing the antibody or antibody
fragment, receptor-mediated endocytosis (see, e.g., Wu and Wu, J.
Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid
as part of a retroviral or other vector, etc. Methods of
administering a prophylactic or therapeutic agent of the invention
include, but are not limited to, parenteral administration (e.g.,
intradermal, intramuscular, intraperitoneal, intravenous and
subcutaneous), epidural administration, intratumoral
administration, and mucosal administration (e.g., intranasal and
oral routes). In addition, pulmonary administration can be
employed, e.g., by use of an inhaler or nebulizer, and formulation
with an aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968,
5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540,
and 4,880,078; and International Appln. Publication Nos. WO
92/19244, WO 97/32572, WO 97/44013, WO 98/31346, and WO 99/66903,
each of which is incorporated herein by reference their entireties.
In one embodiment, an antibody of the invention, combination
therapy, or a composition of the invention is administered using
Alkermes AIR.RTM. pulmonary drug delivery technology (Alkermes,
Inc., Cambridge, Mass.). In a specific embodiment, prophylactic or
therapeutic agents of the invention are administered
intramuscularly, intravenously, intratumorally, orally,
intranasally, pulmonary, or subcutaneously. The prophylactic or
therapeutic agents may be administered by any convenient route, for
example by infusion or bolus injection, by absorption through
epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and
intestinal mucosa, etc.) and may be administered together with
other biologically active agents. Administration can be systemic or
local.
In a specific embodiment, it may be desirable to administer the
prophylactic or therapeutic agents of the invention locally to the
area in need of treatment; this may be achieved by, for example,
and not by way of limitation, local infusion, by injection, or by
means of an implant, said implant being of a porous or non-porous
material, including membranes and matrices, such as sialastic
membranes, polymers, fibrous matrices (e.g., Tissuel.RTM.), or
collagen matrices. In one embodiment, an effective amount of one or
more antibodies of the invention antagonists is administered
locally to the affected area to a subject to prevent, treat,
manage, and/or ameliorate a disorder or a symptom thereof. In
another embodiment, an effective amount of one or more antibodies
of the invention is administered locally to the affected area in
combination with an effective amount of one or more therapies
(e.g., one or more prophylactic or therapeutic agents) other than
an antibody of the invention of a subject to prevent, treat,
manage, and/or ameliorate a disorder or one or more symptoms
thereof.
In another embodiment, the prophylactic or therapeutic agent can be
delivered in a controlled release or sustained release system. In
one embodiment, a pump may be used to achieve controlled or
sustained release (see Langer, supra; Sefton, 1987, CRC Crit. Ref.
Biomed. Eng. 14:20; Buchwald et al., 1980, Surgery 88:507; Saudek
et al., 1989, N. Engl. J. Med. 321:574). In another embodiment,
polymeric materials can be used to achieve controlled or sustained
release of the therapies of the invention (see e.g., Medical
Applications of Controlled Release, Langer and Wise (eds.), CRC
Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability,
Drug Product Design and Performance, Smolen and Ball (eds.), Wiley,
New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev.
Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190;
During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J.
Neurosurg. 7 1:105); U.S. Pat. Nos. 5,679,377; 5,916,597;
5,912,015; 5,989,463; 5,128,326; International Appln. Publication
No. WO 99/15154; and International Appln. Publication No. WO
99/20253. Examples of polymers used in sustained release
formulations include, but are not limited to, poly(2-hydroxy ethyl
methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly
(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides
(PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl
alcohol), polyacrylamide, poly(ethylene glycol), polylactides
(PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters. In
a preferred embodiment, the polymer used in a sustained release
formulation is inert, free of leachable impurities, stable on
storage, sterile, and biodegradable. In yet another embodiment, a
controlled or sustained release system can be placed in proximity
of the prophylactic or therapeutic target, thus requiring only a
fraction of the systemic dose (see, e.g., Goodson, in Medical
Applications of Controlled Release, supra, vol. 2, pp. 115-138
(1984)).
Controlled release systems are discussed in the review by Langer
(1990, Science 249:1527-1533). Any technique known to one of skill
in the art can be used to produce sustained release formulations
comprising one or more therapeutic agents of the invention. See,
e.g., U.S. Pat. No. 4,526,938, International Appln. Publication No.
WO 91/05548, International Appln. Publication No. WO 96/20698, Ning
et al., 1996, "Intratumoral Radioimmunotherapy of a Human Colon
Cancer Xenograft Using a Sustained-Release Gel," Radiotherapy &
Oncology 39:179-189, Song et al., 1995, "Antibody Mediated Lung
Targeting of Long-Circulating Emulsions," PDA Journal of
Pharmaceutical Science & Technology 50:372-397, Cleek et al.,
1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for
Cardiovascular Application," Proc. Int'l. Symp. Control. Rel.
Bioact. Mater. 24:853-854, and Lam et al., 1997,
"Microencapsulation of Recombinant Humanized Monoclonal Antibody
for Local Delivery," Proc. Int'l. Symp. Control Rel. Bioact. Mater.
24:759-760, each of which is incorporated herein by reference in
their entireties.
It should be understood that the antibodies of the invention or
antigen binding portion thereof can be used alone or in combination
with one or more additional agents, e.g., a therapeutic agent (for
example, a small molecule or biologic), said additional agent being
selected by the skilled artisan for its intended purpose. The
additional agent also can be an agent that imparts a beneficial
attribute to the therapeutic composition e.g., an agent that
affects the viscosity of the composition.
It should further be understood that the combinations which are to
be included within this invention are those combinations useful for
their intended purpose. The agents set forth below are illustrative
for purposes and not intended to be limiting. The combinations,
which are part of this invention, can be the antibodies of the
present invention and at least one additional agent selected from
the lists below. The combination can also include more than one
additional agent, e.g., two or three additional agents if the
combination is such that the formed composition can perform its
intended function.
The pharmaceutical compositions of the invention may include a
"therapeutically effective amount" or a "prophylactically effective
amount" of an antibody or antibody portion of the invention. A
"therapeutically effective amount" refers to an amount effective,
at dosages and for periods of time necessary, to achieve the
desired therapeutic result. A therapeutically effective amount of
the antibody or antibody portion may be determined by a person
skilled in the art and may vary according to factors such as the
disease state, age, sex, and weight of the individual, and the
ability of the antibody or antibody portion to elicit a desired
response in the individual. A therapeutically effective amount is
also one in which any toxic or detrimental effects of the antibody,
or antibody portion, are outweighed by the therapeutically
beneficial effects. A "prophylactically effective amount" refers to
an amount effective, at dosages and for periods of time necessary,
to achieve the desired prophylactic result. Typically, since a
prophylactic dose is used in subjects prior to or at an earlier
stage of disease, the prophylactically effective amount will be
less than the therapeutically effective amount.
Having now described the present invention in detail, the same will
be more clearly understood by reference to the following examples,
which are included for purposes of illustration only and are not
intended to limit the scope of the present invention.
EXAMPLES
Example I
Generation and Isolation of 19C7
Identification of Immunoglobulin Genes
Messenger RNA was isolated from subcloned anti-TnI 19C7-144
hybridoma cells. (Hybridoma cell line TnI 19C7 is described in U.S.
Patent Application Publication No. US2006/0018897.) TnI 19C7 mRNA
was utilized in a reverse transcriptase-polymerase chain reaction
using a mouse Ig primer set kit purchased from Novagen (Novagen
(which is an Affiliate of Merck KGaA, Darmstadt, Germany), Cat No.
69831-3) with immunoglobulin gene specific primers contained in the
kit. The resulting PCR products were sequenced and thus the
immunoglobulin variable heavy and variable light chain genes were
identified (see FIG. 2).
Cloning TnI 19C7 Variable Region Genes into pYD41 Vector
A yeast display system was used to express unmutated or wild-type
anti-TnI proteins (described herein infra) and a library of
anti-TnI proteins on the yeast surface as a fusion to the yeast
protein AGA2. A yeast display vector called pYD (Invitrogen,
Carlsbad, Calif.) was used as it allows for cloning of the anti-TnI
gene at the C-terminus of the AGA2 gene, a yeast mating factor
(See, Boder and Wittrup, Nature Biotechnology, 15:553-557 (June
1997)). Other critical features of the pYD vector include a
galactose inducible promoter and an epitope tag, V5, on the
C-terminus of the inserted anti-TnI gene (see FIG. 12).
The yeast display platform utilizes an antibody format known as the
single-chain variable fragment. In the scFv format, the variable
heavy domain is connected to the variable light domain through a
flexible linker (variable heavy domain--Linker GPAKELTPLKEAKVS (SEQ
ID NO:58)--variable light domain).
PCR single overlap extension (SOE) was used to combine the variable
heavy (VH) and the variable light genes (VL) for the TnI 19C7 scFv
construct (FIG. 2, and SEQ ID NOs:54 and 55). The TnI 19C7 scFv DNA
was cloned into the yeast display vector pYD41 using vector
restriction sites SfiI and XhoI. The pYD41-TnI 19C7scFv vector was
transformed into DH5.alpha. E. coli. Plasmid DNA was then isolated
from the E. coli and the TnI 19C7 scFv insert was sequenced to
ensure the scFv was cloned in frame with the AGA2 protein.
The cloning site for the scFv into the yeast display vector pYD41
is in an ORF that includes the following genes: AGA2-tether linker
41-X press epitope tag-TnI 19C7 variable heavy chain-Linker 40-TnI
19C7 variable light chain-V5 epitope tag--Six His tag (SEQ ID NO:
29). In addition, the yeast strain EBY100 is a tryptophan auxotroph
and the pYD41 vector encodes for tryptophan as the system's
selectable marker.
Transformation into Saccharomyces cerevisiae Strain EBY100
Yeast display plasmid, pYD41-TnI 19C7 scFv, was transformed into S.
cerevisiae EBY100 using the Gietz and Schiestl Method (See Schiestl
and Gietz, Current Genetics, 16(5-6):339-46 (December 1989)).
Dilutions of the transformation reaction were plated on selective
glucose plates (2% glucose (0.67% yeast nitrogen base, 0.105%
HSM-trp-ura, 1.8% bacterial agar, 18.2% sorbitol, 0.86%
NaH.sub.2PO.sub.4 H.sub.2O, 1.02% Na.sub.2HPO.sub.4 7H.sub.2O)) and
incubated at 30.degree. C. for 48-72 hours. Selective glucose media
was inoculated with individual colonies and grown shaking at
30.degree. C. for 16-20 hours. Protein expression was induced in
colonies by transferring 0.5 OD600 of cells/ml (1e7 cells/0.50
D/ml) to selective galactose media. Colonies were shaken at
20.degree. C. for 16-24 hours and then analyzed by the FACS Aria
flow cytometer for binding to scTnI-C-2 and anti-V5. (It should be
noted that scTnI-C-2 is a linked, single-chain TnI
(28-110aa)-linker-TnC (1-160aa) from Spectral Diagnostics, Toronto,
Canada. ScTnI-C-2 is abbreviated as "scTnI-C" for purposes of the
present discussion.) For flow cytometry assays, yeast cells
expressing TnI 19C7 scFv incubated with scTnI-C-2 or anti-V5
followed by either anti-troponin mAb and goat anti
mouse-phycoerythrin (GAM:PE) (FIG. 3B) or GAM:PE respectively (FIG.
3A). The flow cytometry histograms illustrate the full-length
expression of TnI 19C7 scFv as detected by anti-V5 and the ability
of TnI 19C7 scFv to bind to scTnI-C-2.
Off-Rate Analysis for TnI 19C7 scFv and TnI 19C7 Variants on
Yeast
Off-rate measurements of TnI 19C7 scFv and TnI 19C7 variants on
yeast were measured by incubating 0.05OD yeast (1.times.10.sup.6
cells) with 50 nM scTnI-C-2 for 30-60 minutes at room temperature.
Cells were then washed twice with blocking buffer containing
phosphate buffered saline pH 6.8 with 2% bovine serum albumin and
0.2% Standapol ES-1 (PBS/BSA/Standapol) and incubated at room
temperature for varying amounts of time (0, 0.25 hr, 0.5 hr, 1 hr,
2 hr, 4.25 hr, 25.5 hr, 50 hr 75 hr and 144 hr (see FIG. 4). At
each individual time point, yeast cells were transferred to ice to
halt the reaction. Cells were then washed twice with blocking
buffer and suspended in the next staining reagent, specifically,
anti-TnI mAb 8E10 at 100 nM. Cells were incubated on ice for 30
minutes, washed twice and then incubated with goat anti
mouse-phycoerythrin (GAM:PE). Finally, the cells were washed and
analyzed on the FACS Aria flow cytometer. FIG. 4 shows the off-rate
data plotted as mean fluorescence units ("MFU") versus time (in
seconds). A first order decay equation was used to fit the data.
The off-rate, m2 in the equation shown in FIG. 4, was fitted to
0.007 sec.sup.-1. The TnI 19C7 scFv half-life (t.sub.1/2) was
approximately 8.5 min (t.sub.1/2=ln 2/k.sub.off).
An off-rate sorting strategy was used to identify off-rate improved
TnI 19C7 variants from mutagenic libraries. Therefore, the TnI 19C7
scFv, unmutated or wildtype ("wt"), half-life was used to determine
the appropriate time to sort the mutagenic libraries. TnI 19C7
mutagenic libraries were sorted approximately 9 min after washing
cells free of scTnI-C-2 with the same assay conditions described
for wt TnI 19C7 scFv.
Equilibrium Disassociation (KD) Analysis for TnI 19C7 scFv and
TnI
KD measurements of TnI 19C7 scFv and TnI 19C7 variants on yeast
were measured by incubating 0.05 OD yeast (1.times.10.sup.6 cells)
with varying concentrations of scTnI-C-2 for 45-60 minutes at room
temperature. Blocking buffer containing phosphate buffered saline
pH 6.8 with 2% bovine serum albumin and 0.2% Standapol ES-1
(PBS/BSA/Standapol) was used for washes and reagent dilutions.
Cells were then washed twice and incubated for 30 min with anti-TnI
mAb, 8E10. Cells were washed again and incubated with goat
anti-mouse phycoerythrin for 30 min. Finally, cells were washed and
analyzed on the FACS Aria flow cytometer (see FIG. 5). FIG. 5 shows
the KD data plotted as normalized mean fluorescence units ("MFU")
versus concentration scTn-I-C-2 (in Molarity). The
antibody-normalized, antigen-binding mean fluorescence intensity
was plotted against antigen concentration and a non-linear least
squares fit (y=m1+m2*m0/(m3+m0)) was used to determine K.sub.D.
Generation of TnI 19C7 Spiked CDR Libraries
Mutagenesis was directed to the three heavy and three light chain
complementary determining regions (CDR) of antibody TnI 19C7 since
these loops are the major antigen contact sites. CDR loop lengths
and numbering were defined using Kabat and Oxford's Molecular AbM
modeling nomenclature. Individual libraries were composed such that
random mutations are incorporated at each amino acid position of
the CDR for a single library. A total of six libraries were
generated corresponding to one library per each CDR.
Libraries were generated by combining SfiI/XhoI digested. pYD41
vector and PCR products with chemically competent EBY100 yeast (see
FIG. 7). Two PCR products were generated for each CDR library to
allow for PCR sorting and homologous recombination into yeast. One
PCR product used a primer that was designed, such that for the
entire length of the CDR, a 70% wild type to 30% other nucleotide
ratio was used in the primer synthesis. This product was called the
spiked (sp) product (see FIG. 7). The second PCR product was
designed to include the remaining portion of the scFv gene. The two
PCR products were combined and used to generate a single-chain
variable fragment or a scFv product. Digested vector (1 ug) and the
scFv PCR products (5 ug) were combined with EBY100 yeast
(5.2e8-6.4e8 cells) and transformed using electroporation. The scFv
PCR product and the pYD41 digested vector cyclize during
transformation due to homologous recombination facilitated by the
nucleotide overlap and the mechanism of yeast endogenous gap
repair. Libraries were grown at 30.degree. C. for 48-72 hours in
selective glucose media and passed again in selective glucose media
prior to induction of protein expression for library sorting.
TnI 19C7 Mutagenic CDR Libraries
TnI 19C7 libraries were sorted based on an off-rate sorting
strategy. TnI 19C7 CDR mutagenic libraries were induced in
galactose expression media at 20.degree. C. for 18-24 hours. TnI
19C7 scFv and TnI 19C7 libraries on yeast were incubated with 25-50
nM scTnI-C-2 for 10-15 minutes at room temperature. Cells were then
washed twice with blocking buffer containing phosphate buffered
saline pH 6.8 with 2% bovine serum albumin and 0.2% Standapol ES-1
(PBS/BSA/Standapol) and incubated at room temperature for 8 min.
Yeast cells were transferred to ice to halt the reaction. Cells
were then washed twice with blocking buffer and suspended in the
next staining reagent, specifically, anti-TnI mAb 8E10 at 100 nM
and anti-V5 at 1.5-2 ug/ml. Cells were incubated on ice for 30
minutes, washed twice and then incubated with 1:200 goat anti
mouseIgG2a-phycoerythrin (GAMIgG2a:PE) and with 1:200 dilution goat
anti mouseIgG1-Alexa Fluor488 (GAMIgG1:488). Finally, the cells
were washed, analyzed, and sorted on the FACS Aria flow cytometer.
Sort gates were set based on unmutated TnI 19C7 binding at 8-9 min
with a gate set to sort full-length TnI binding clones. Each sort
collected the top 0.1-0.5% of the TnI binding population. Sorted
cells were grown in selective glucose media and grown 18-24 hours
at 30.degree. C. Sort 1 cells were induced and sorting was repeated
for two or three additional rounds.
After the last sort, sorted cells were plated onto selective
glucose plates and placed at 30.degree. C. for 72 hours. Individual
yeast colonies from these libraries were inoculated in selective
glucose media, cryopreserved and induced in selective galactose
media. Individual colonies were then characterized and ranked in an
off-rate assay. TnI 19C7 AM4 was isolated and identified from this
sorting output.
Generation and Analysis of TnI 19C7 Combinatorial Mutant Clones
Clones that were characterized for off-rate from each master CDR
library or the total master CDR library output were used to
construct scFv genes containing different pairings of the
individual mutations. This approach enabled determination of
whether the binding properties were further enhanced upon combining
individual mutations. Combinatorial clones containing various
mutations in each CDR region were constructed by PCR amplification
and combined using routine techniques known to those skilled in the
art. Combinatorial mutant libraries were transformed into yeast as
described above and sorted two times using off-rate and KD
selection pressures. For KD selection, 100 pM (round 1) and 50 pM
(round 2) scTnI-C were used in the KD experiment as described above
(FIG. 5). For off-rate sorting, sorting was conducted as described
above with incubation times following washing away of antigen of 3
hr 40 min (round 1) and 4 hrs 25 min (round 2). Sort gates were set
based on unmutated TnI 19C7 binding for each condition with a gate
set to sort full-length TnI binding clones. Each sort collected the
top 0.1% of the TnI binding population. Sorted cells were grown in
selective glucose media for 18-24 hours at 30.degree. C. Sort 1
cells were induced and sorting was repeated for one additional
round.
After the last sort, sorted cells were plated onto selective
glucose plates and placed at 30.degree. C. for 72 hours. Individual
yeast colonies from these libraries were inoculated in selective
glucose media, cryopreserved and induced in selective galactose
media. Individual colonies were then characterized and ranked in an
off-rate assay. TnI 19C7 AM1, AM2, and AM3 were isolated and
identified from this combinatorial library.
Analysis of Selected TnI 19C7 Variants
Selected clones were initially characterized for improvements in KD
as described above for wild type TnI 19C7 scFv. FIG. 9 shows the
scFv KD values determined for four selected clones. The TnI 19C7
AM1 clone exhibited the most improved binding at 0.36 nM compared
to the wild-type TnI 19C7 antibody 1.7 nM.
Selected TnI 19C7 scFv variants were sequenced to determine the
amino acid mutations being expressed. Initially, plasmid DNA was
isolated from yeast suspension cultures using a yeast mini-prep kit
(Cat No. D2001, Zymo Research Orange, Calif.). In order to obtain
sequencing grade plasmid DNA, plasmid from the yeast mini-prep kit
was transformed into DH5.alpha. E. coli, and then purified from
culture using E. coli mini-prep kits (Qiagen). Pure plasmid DNA was
then sequenced using pYD41 vector specific primers (pYD41
for-TAGCATGACTGGTGGACAGC (SEQ ID NO:59) and
pYD41rev-CGTAGAATCGAGACCGAG (SEQ ID NO:60)) Amino acid sequence
data for TnI 19C7 scFv variants is shown in FIG. 13. Position
numbers refers to amino acid position in the respective CDR (as
numbered using Kabat method).
Overall the source of sequence diversity from the wild-type clone
was found in the CDR L2 and CDR H1, whereas CDR L1 and H3 folded
into a consensus motif. The CDR L3 and CDR H2 remained unmutated.
The sequence data for CDR H1 indicated a preference for a
conservative change at position 34 from isoleucine to leucine as
identified in the 3 clones isolated from the combinatorial library.
The consensus sequence for CDR H3 indicated a strong preference at
position 100a for tyrosine instead of tryptophan, at position 101
for threonine instead of alanine, and at position 102 for aspartate
instead of tyrosine as identified in the 3 clones isolated from the
combinatorial library. From the master CDR sorting in which clone
19C7 AM4 was identified, the CDR H3 was the only CDR with mutations
that were different than the combinatorial consensus set of
sequences. Specifically the mutations were Ala96Phe, Tyr99Ser,
Trp100aAla, and Tyr102Asp.
The consensus sequence data for CDR L1 indicated a preference for
threonine at position 25, lysine at position 27, asparagine at
position 28, valine at position 29, and histidine at position 34.
For the CDR L2, each clone has unique or no mutations with only TnI
19C7 AM1 and AM2 sharing only the Ser54Arg mutation.
Cloning and Soluble Expression of TnI 19C7 Chimeric Antibodies in a
Transient or Stable Expression System
Selected TnI 19C7 variants were converted to chimeric mouse-mouse
IgG.sub.2.alpha./mouse kappa and/or mouse-human IgG.sub.1/human
kappa antibodies through cloning of the TnI 19C7 variable domains
into the transient expression vector system called pBOS (Abbott
Bioresearch Center, Worcester, Mass.). More specifically, PCR was
used to amplify the variable heavy and variable light chain genes
with restriction sites for cloning into separate pBOS vectors
(Mizushima and Nagata, Nucleic Acids Research, 18:5322 (1990)). The
variable heavy and variable light genes were ligated in digested
and dephosphorylated vector and transformed into DH5.alpha. E.
coli. Plasmid DNA was purified from E. coli and transfected into
293H cells using PEI (1 mg/ml). Transient antibody was expressed
for the following TnI 19C7 variants: TnI 19C7 wt, AM1, AM2, AM3 and
AM4.
For example, using the pBOS-TnI 19C7 AM1 heavy and light vectors, a
stable CHO cell line plasmid was created in a two-step cloning
procedure. First, variable heavy chain and variable light genes
were ligated in frame to the human constant genes in pBV and pJV
plasmids (Abbott Bioresearch Center, Worcester, Mass.),
respectively, using the restriction enzymes SrfI/NotI. Ligation
reactions were transformed into DH5.alpha. E. coli and plasmid DNA
was subsequently isolated from individual colonies. The pBV-TnI
19C7 mouse variable heavy-human IgG1 and pJV-TnI 19C7 mouse
variable light-human kappa were sequenced at the cloning sites.
The second cloning step involved combining the heavy chain
IgG.sub.1 genes and the light chain kappa genes into a single
stable cell line vector. The pBV-TnI 19C7 AM1 human IgG1 and
pJV-TnI 19C7 AM1 human kappa vectors were digested with AscI/PacI.
The VL-human kappa constant and the VH-human IgG1 constant DNA
fragments were gel purified and ligated to produce the stable cell
line vector called pBJ-TnI 19C7 AM1. The pBJ-TnI 19C7 AM1 human
heavy/light chimeric plasmid was transformed into CHO cells using a
lipofectamine (Invitrogen) protocol. Stable cell lines were
sub-cloned from initial transformation. A stable CHO cell line has
been developed for the clone AM1 (also referred to as "TnI 19C7AM1
hG1kCHO204") and was deposited with the American Type Culture
Collection, 10801 University Boulevard, Manassas, Va. 20110-2209 on
Feb. 11, 2009 and received deposit designation PTA-9816.
Example II
Relative Affinity of Troponin I Clone 19C7 Wild Type and Affinity
Matured Antibodies
Troponin I clone 19C7 wild type (full mouse construct) and affinity
matured (human constant region) antibodies were evaluated for
relative affinity in a microtiter enzyme immunoassay. 96-well assay
plates (NUNC Corporation, Rochester, N.Y.) were coated by adding
100 uL/well of a 2 ug/mL solution of either sheep anti-mouse IgG
Fc.gamma. specific antibody (Jackson ImmunoResearch, West Grove,
Pa.) or donkey antihuman IgG Fc.gamma. fragment specific antibody
(Jackson ImmunoResearch). Both antibodies were diluted in phosphate
buffered saline (PBS, Abbott Laboratories, Abbott Park, Ill.). The
assay plates were incubated overnight at 15-30 deg C. The next day
the coating reagent was removed and 200 uL/well of BSA solution
(bovine serum albumin [Abbott Laboratories] diluted in PBS) was
added. The BSA solution was incubated in the assay wells for 30
minutes at 15-30 deg C., removed and the assay wells washed by
adding 300 uL/well distilled water (dH2O, Abbott Laboratories) and
aspirating for three wash cycles. Next, 100 uL/well test samples
were added. Test samples were prepared by creating an initial 2
ug/mL solution (in BSA solution) of each antibody, followed by log
3 dilutions, in BSA solution. The test samples were incubated for
2-3 hours at 15-30 deg C. after which they were aspirated away and
the wells washed with dH2O as described above. Next, 100 uL/well of
test antigen solutions were added to each assay well. The test
antigen solutions were created by first preparing a 1000 ng/mL
solution of scTnI-C-2 (aa 28-100 of cardiac troponin I linked to
full length cardiac troponin C, Spectral Diagnostics) in BSA
solution, followed by log 2 dilutions. The antigen solutions were
incubated in the assay wells for 10 minutes at 15-30 deg C. and
then removed by slapping out the solutions. The assay plates were
then washed with dH2O as previously described. Next, 100 uL/well of
biotin labeled goat anti-troponin I antibody (HyTest, diluted to
500 ng/mL in BSA solution) was added to each assay well and
incubated for 30 minutes at 15-30 deg C. The antibody was then
aspirated away and the wells washed with dH2O as described. Next,
100 uL/well of a 200 ng/mL solution (in BSA solution) of horse
radish peroxidase labeled streptavidin (SA-HRPO, Jackson
ImmunoResearch) was added and incubated for 30 minutes at 15-30 deg
C. The SA-HRPO reagent was then aspirated away and the plates
washed as described. Next, substrate solution was prepared by
dissolving 1 OPD tablet per 10 mL OPD diluent (o-phenylenediamine,
both Abbott Laboratories). 100 uL/well of the prepared substrate
solution was added to the assay plates, incubated for about 4-5
minutes and then the reaction quenched by adding 100 uL/well 1N
sulfuric acid (Abbott Laboratories). The resulting signal was read
at 492 nm using an optical fluorometer. Results from the experiment
were plotted using kaleidagraph software. The Ag.sub.50 value (the
concentration of antigen at 50% of maximal binding) was determined
and used to compare the antibodies for relative affinity to the
tested antigen.
Example III
Use of Monoclonal Antibody 19C7 in an Immunoassay
Troponin I clone 19C7 wild type (full mouse construct) and affinity
matured (human constant region) antibodies were evaluated for
relative affinity on the ARCHITECT.RTM. immunoassay analyzer
(Abbott Laboratories). The assay was fully automated, and the
analyzer performs all steps. Magnetic microparticles coated with a
mouse anti-troponin I antibody (Abbott Laboratories, Abbott Park,
Ill.) were mixed with varying levels of scTnI-C-2 (aa 28-100 of
cardiac troponin I linked to full length cardiac troponin C
(Spectral Diagnostics) and incubated for 18 minutes at 15-30 deg C.
During this time, the microparticle coated antibody bound the
scTnI-C-2. The microparticles were then attracted to a magnet, the
remaining assay solution was aspirated, and the particles washed
with assay diluent (Abbott Laboratories, Abbott Park, Ill.). Next,
the wild type or affinity matured 19C7 antibodies, all of which
were labeled with acridinium (Abbott Laboratories, Abbott Park,
Ill.) were added to the microparticles and incubated for 4 minutes
at 15-30 deg C. Next, the microparticles were attracted to a
magnet, the remaining assay solution was aspirated, and the
particles were washed with assay diluent. Signal (relative light
units) was generated by the addition of pre-trigger and trigger
solutions (both Abbott Laboratories). Signal ratios were calculated
and used to compare antibodies. As can be established based upon
the results shown in FIG. 11, AM1 antibody gave a better signal
than wild-type antibody.
SEQUENCE LISTINGS
1
112148DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 1gaattcgcgg cccagccggc catggccgag gtccagcttc
agcagtca 48245DNAArtificial SequenceDescription of Artificial
Sequence Synthetic primer 2cttcaggggc gtcaactcct tggcgggacc
tgcagagaca gtgac 45345DNAArtificial SequenceDescription of
Artificial Sequence Synthetic primer 3ttgacgcccc tgaaggaggc
gaaggtctct gacatcttgc tgact 45445DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 4gaagggccct ctagactcga
gggcggccgc ccgttttatt tccag 45591DNAArtificial SequenceDescription
of Artificial Sequence Synthetic primer 5gaaacctggg gcctcagtga
ggatatcctg caaggcttct ggatacacat tcactgacta 60caacatacac tgggtgaaac
agagccatgg a 91630DNAArtificial SequenceDescription of Artificial
Sequence Synthetic primer 6agaagccttg caggatatcc tcactgaggc
30722DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 7agtaacgttt gtcagtaatt gc 228108DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
8agccatggaa agagccttga gtggattgga tatatttatc cttacaatgg tattactggc
60tacaaccaga aattcaagag caaggccaca ttgactgtag acagttcc
108930DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 9tccaatccac tcaaggctct ttccatggct
301092DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 10catctgagga ctctgcagtc tatttttgtg ctagagacgc
ttatgattac gactggttgg 60cttactgggg ccaagggact ctggtcactg tc
921130DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 11tctagcacaa aaatagactg cagagtcctc
301295DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 12ctgtgagtcc aggagaaaga gtcagtttct cctgcagggc
cagtcagagc attggcacaa 60acatatattg gtatcagcaa agaacaaatg gttct
951330DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 13gcaggagaaa ctgactcttt ctcctggact
301483DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 14aaagaacaaa tggttctcca aggcttctca taaagtatgc
ttctgagtct atctctggga 60tcccttccag gtttagtggc agt
831527DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 15ctttatgaga agccttggag aaccatt
271688DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 16gtgtggagtc tgaagatatt gctgattatt actgtcaaca
aataataact ggccatacac 60gttcggaggg gggaccaagc tggaaata
881727DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 17acagtaataa tcagcaatat cttcaga
271827DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 18atagaaaagg atattacatg ggaaaac
271930DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 19tgggtgaaac agagccatgg aaagagcctt
302025DNAArtificial SequenceDescription of Artificial Sequence
Synthetic primer 20aaggccacat tgactgtaga cagtt 252118DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
21tggtatcagc aaagaaca 182224DNAArtificial SequenceDescription of
Artificial Sequence Synthetic primer 22gggatccctt ccaggtttag tggc
2423357DNAArtificial SequenceDescription of Artificial Sequence
Synthetic polynucleotide 23gag gtc cag ctt cag cag tca gga cct gac
ctg gtg aaa cct ggg gcc 48Glu Val Gln Leu Gln Gln Ser Gly Pro Asp
Leu Val Lys Pro Gly Ala 1 5 10 15 tca gtg agg ata tcc tgc aag gct
tct gga tac aca ttc acg gac tat 96Ser Val Arg Ile Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 aac tta cac tgg gtg aaa
cag agc cat gga aag agc ctt gag tgg att 144Asn Leu His Trp Val Lys
Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 gga tat att tat
cct tac aat ggt att act ggc tac aac cag aaa ttc 192Gly Tyr Ile Tyr
Pro Tyr Asn Gly Ile Thr Gly Tyr Asn Gln Lys Phe 50 55 60 aag agc
aag gcc aca ttg act gta gac agt tcc tcc aat aca gcc tac 240Lys Ser
Lys Ala Thr Leu Thr Val Asp Ser Ser Ser Asn Thr Ala Tyr 65 70 75 80
atg gac ctc cgc agc ctg aca tct gag gac tct gca gtc tat ttt tgt
288Met Asp Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95 gct aga gac gct tat gat tac gac tat ctg acg gac tgg ggc
caa ggg 336Ala Arg Asp Ala Tyr Asp Tyr Asp Tyr Leu Thr Asp Trp Gly
Gln Gly 100 105 110 act ctg gtc act gtc agc gct 357Thr Leu Val Thr
Val Ser Ala 115 24119PRTArtificial SequenceSynthetic Construct
24Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala 1
5 10 15 Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Tyr 20 25 30 Asn Leu His Trp Val Lys Gln Ser His Gly Lys Ser Leu
Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Pro Tyr Asn Gly Ile Thr Gly
Tyr Asn Gln Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp
Ser Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Asp Leu Arg Ser Leu Thr
Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Ala Tyr
Asp Tyr Asp Tyr Leu Thr Asp Trp Gly Gln Gly 100 105 110 Thr Leu Val
Thr Val Ser Ala 115 25357DNAArtificial SequenceDescription of
Artificial Sequence Synthetic polynucleotide 25ctccaggtcg
aagtcgtcag tcctggactg gaccactttg gaccccggag tcactcctat 60aggacgttcc
gaagacctat gtgtaagtgc ctgatattga atgtgaccca ctttgtctcg
120gtacctttct cggaactcac ctaacctata taaataggaa tgttaccata
atgaccgatg 180ttggtcttta agttctcgtt ccggtgtaac tgacatctgt
caaggaggtt atgtcggatg 240tacctggagg cgtcggactg tagactcctg
agacgtcaga taaaaacacg atctctgcga 300atactaatgc tgatagactg
cctgaccccg gttccctgag accagtgaca gtcgcga 35726119PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
26Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala 1
5 10 15 Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp
Tyr 20 25 30 Asn Leu His Trp Val Lys Gln Ser His Gly Lys Ser Leu
Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Pro Tyr Asn Gly Ile Thr Gly
Tyr Asn Gln Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp
Ser Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Asp Leu Arg Ser Leu Thr
Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Asp Ala Tyr
Asp Tyr Asp Tyr Leu Thr Asp Trp Gly Gln Gly 100 105 110 Thr Leu Val
Thr Val Ser Ala 115 27324DNAArtificial SequenceDescription of
Artificial Sequence Synthetic polynucleotide 27gac atc ttg ctg act
cag tca tcc agt ctc ctg tct gtg agt cca gga 48Asp Ile Leu Leu Thr
Gln Ser Ser Ser Leu Leu Ser Val Ser Pro Gly 1 5 10 15 gaa aga gtc
agt ttc tcc tgc agg acc agt aag aac gtt ggc aca aac 96Glu Arg Val
Ser Phe Ser Cys Arg Thr Ser Lys Asn Val Gly Thr Asn 20 25 30 att
cat tgg tat cag caa aga aca aat ggt tct cca agg ctt ctc ata 144Ile
His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 35 40
45 aag tat gct tca gag cgt tta cct ggg atc cct tcc agg ttt agt ggc
192Lys Tyr Ala Ser Glu Arg Leu Pro Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60 agt ggg tca ggg aca gat ttt act ctt agc atc aac agt gtg
gag tct 240Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val
Glu Ser 65 70 75 80 gaa gat att gct gat tat tac tgt caa caa agt aat
aac tgg cca tac 288Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asn
Asn Trp Pro Tyr 85 90 95 acg ttc gga ggg ggg acc aag ctg gaa ata
aaa cgg 324Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105
28108PRTArtificial SequenceSynthetic Construct 28Asp Ile Leu Leu
Thr Gln Ser Ser Ser Leu Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg
Val Ser Phe Ser Cys Arg Thr Ser Lys Asn Val Gly Thr Asn 20 25 30
Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 35
40 45 Lys Tyr Ala Ser Glu Arg Leu Pro Gly Ile Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser
Val Glu Ser 65 70 75 80 Glu Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser
Asn Asn Trp Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu
Ile Lys Arg 100 105 29324DNAArtificial SequenceDescription of
Artificial Sequence Synthetic polynucleotide 29ctgtagaacg
actgagtcag aggtcagtag gacagacact caggtcctct ttctcagtca 60aagaggacgt
cctggtcatt cttgcaaccg tgtttgtaag taaccatagt cgtttcttgt
120ttaccaagag gttccgaaga gtatttcata cgaagtctcg caaatggacc
ctagggaagg 180tccaaatcac cgtcacccag tccctgtcta aaatgagaat
cgtagttgtc acacctcaga 240cttctataac gactaataat gacagttgtt
tcattattga ccggtatgtg caagcctccc 300ccctggttcg acctttattt tgcc
32430108PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 30Asp Ile Leu Leu Thr Gln Ser Ser Ser Leu Leu
Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Val Ser Phe Ser Cys Arg Thr
Ser Lys Asn Val Gly Thr Asn 20 25 30 Ile His Trp Tyr Gln Gln Arg
Thr Asn Gly Ser Pro Arg Leu Leu Ile 35 40 45 Lys Tyr Ala Ser Glu
Arg Leu Pro Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser 65 70 75 80 Glu
Asp Ile Ala Asp Tyr Tyr Cys Gln Gln Ser Asn Asn Trp Pro Tyr 85 90
95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105
316PRTArtificial SequenceDescription of Artificial Sequence
Synthetic 6xHis tag 31His His His His His His 1 5
3210PRTUnknownDescription of Unknown Unknown wild-type peptide
32Gly Tyr Thr Phe Thr Asp Tyr Asn Ile His 1 5 10 3310PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 33Gly
Tyr Thr Phe Thr Asp Tyr Asn Leu His 1 5 10 3410PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 34Gly
Tyr Thr Phe Thr Asp Tyr Asn Leu His 1 5 10 3510PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 35Gly
Tyr Ser Phe Thr Asp Tyr Asn Leu His 1 5 10 3610PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 36Gly
Tyr Thr Phe Thr Asp Tyr Asn Ile His 1 5 10
3710PRTUnknownDescription of Unknown Unknown wild-type peptide
37Asp Ala Tyr Asp Tyr Asp Trp Leu Ala Tyr 1 5 10 3810PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 38Asp
Ala Tyr Asp Tyr Asp Tyr Leu Thr Asp 1 5 10 3910PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 39Asp
Ala Tyr Asp Tyr Asp Tyr Leu Thr Asp 1 5 10 4010PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 40Asp
Ala Tyr Asp Tyr Asp Tyr Leu Thr Asp 1 5 10 4110PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 41Asp
Phe Tyr Asp Ser Asp Ala Leu Ala Asp 1 5 10
4211PRTUnknownDescription of Unknown Unknown wild-type peptide
42Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile Tyr 1 5 10
4311PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 43Arg Thr Ser Lys Asn Val Gly Thr Asn Ile His 1 5
10 4411PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 44Arg Thr Ser Lys Asn Val Gly Thr Asn Ile His 1 5
10 4511PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 45Arg Thr Ser Lys Asn Val Gly Thr Asn Ile His 1 5
10 4611PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 46Arg Ala Ser Gln Ser Ile Gly Thr Asn Ile Tyr 1 5
10 477PRTUnknownDescription of Unknown Unknown wild-type peptide
47Tyr Ala Ser Glu Ser Ile Ser 1 5 487PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 48Tyr
Ala Ser Glu Arg Leu Pro 1 5 497PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 49Tyr Gly Thr Glu Arg Val Phe
1 5 507PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 50Tyr Ala Ser Glu Ser Ile Ser 1 5
517PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 51Tyr Ala Ser Glu Ser Ile Ser 1 5 52330PRTHomo
sapiens 52Ala Ser Thr Lys Gly Pro Ser Val Phe Phe Leu Ala Pro Ser
Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn
Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val
Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115
120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235
240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser
Leu Ser Leu Ser Pro Gly Lys 325 330 53330PRTHomo sapiens 53Ala Ser
Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20
25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys
Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Ala
Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150
155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275
280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330 5410PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 54Gly Tyr Thr Phe Thr Asp Tyr Asn Leu
His 1 5 10 5517PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 55Tyr Ile Tyr Pro Tyr Asn Gly Ile Thr
Gly Tyr Asn Gln Lys Phe Lys 1 5 10 15 Ser 569PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 56Asp
Ala Tyr Asp Tyr Asp Leu Thr Asp 1 5 5711PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 57Arg
Thr Ser Lys Asn Val Gly Thr Asn Ile His 1 5 10 587PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 58Tyr
Ala Ser Glu Arg Leu Pro 1 5 599PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 59Gln Gln Ser Asn Asn Trp Pro
Tyr Thr 1 5 6015PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 60Gly Pro Ala Lys Glu Leu Thr Pro Leu
Lys Glu Ala Lys Val Ser 1 5 10 15 6120DNAArtificial
SequenceDescription of Artificial Sequence Synthetic primer
61tagcatgact ggtggacagc 206218DNAArtificial SequenceDescription of
Artificial Sequence Synthetic primer 62cgtagaatcg agaccgag
1863106PRTHomo sapiens 63Thr Val Ala Ala Pro Ser Val Phe Ile Phe
Pro Pro Ser Asp Glu Gln 1 5 10 15 Leu Lys Ser Gly Thr Ala Ser Val
Val Cys Leu Leu Asn Asn Phe Tyr 20 25 30 Pro Arg Glu Ala Lys Val
Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 35 40 45 Gly Asn Ser Gln
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 50 55 60 Tyr Ser
Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 65 70 75 80
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 85
90 95 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 64105PRTHomo
sapiens 64Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser
Ser Glu 1 5 10 15 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu
Ile Ser Asp Phe 20 25 30 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys
Ala Asp Ser Ser Pro Val 35 40 45 Lys Ala Gly Val Glu Thr Thr Thr
Pro Ser Lys Gln Ser Asn Asn Lys 50 55 60 Tyr Ala Ala Ser Ser Tyr
Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 65 70 75 80 His Arg Ser Tyr
Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 85 90 95 Lys Thr
Val Ala Pro Thr Glu Cys Ser 100 105 6510PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 65Gly
Tyr Xaa Phe Thr Asp Tyr Asn Xaa His 1 5 10 6617PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 66Tyr
Ile Tyr Pro Tyr Asn Gly Ile Thr Gly Tyr Asn Gln Lys Phe Lys 1 5 10
15 Ser 6710PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 67Asp Xaa Tyr Asp Xaa Asp Xaa Leu Xaa Xaa 1 5 10
6811PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 68Arg Xaa Ser Xaa Xaa Xaa Gly Thr Asn Ile Xaa 1 5
10 697PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 69Tyr Xaa Xaa Glu Xaa Xaa Xaa 1 5
709PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 70Gln Gln Ser Asn Asn Trp Pro Tyr Thr 1 5
7130PRTMus sp. 71Glu Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val
Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly
Phe Ser Leu Ser 20 25 30 7214PRTMus sp. 72Trp Ile Arg Gln Pro Pro
Gly Lys Ala Leu Glu Trp Leu Ala 1 5 10 7332PRTMus sp. 73Arg Leu Thr
Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr 1 5 10 15 Met
Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg 20 25
30 7411PRTMus sp. 74Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5
10 7530PRTMus sp. 75Glu Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val
Lys Pro Thr Glu 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Val Ser Gly
Phe Ser Leu Ser 20 25 30 7614PRTMus sp. 76Trp Ile Arg Gln Pro Pro
Gly Lys Ala Leu Glu Trp Leu Ala 1 5 10 7732PRTMus sp. 77Arg Leu Thr
Ile Ser Lys Asp Thr Ser Lys Ser Gln Val Val Leu Thr 1 5 10 15 Met
Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg 20 25
30 7811PRTMus sp. 78Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5
10 7930PRTMus sp. 79Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser 20 25 30 8014PRTMus sp. 80Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val Gly 1 5 10 8132PRTMus sp. 81Arg Phe Thr
Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln 1 5 10 15 Met
Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25
30 8211PRTMus sp. 82Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5
10 8330PRTMus sp. 83Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe Ser 20 25 30 8414PRTMus sp. 84Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val Ser 1 5 10 8532PRTMus sp. 85Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln 1 5 10 15 Met
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25
30 8611PRTMus sp. 86Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5
10 8730PRTMus sp. 87Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Gly Thr Phe Ser 20 25 30 8814PRTMus sp. 88Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met Gly 1 5 10 8932PRTMus sp. 89Arg Val Thr
Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu 1 5 10 15 Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25
30 9011PRTMus sp. 90Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5
10 9130PRTMus sp. 91Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Tyr Thr Phe Thr 20 25 30 9214PRTMus sp. 92Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met Gly 1 5 10 9332PRTMus sp. 93Arg Val Thr
Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu 1 5 10 15 Leu
Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg 20 25
30 9411PRTMus sp. 94Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5
10 9523PRTMus sp. 95Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala
Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys 20 9615PRTMus
sp. 96Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr 1
5 10 15 9732PRTMus sp. 97Gly Val Pro Asp Arg Phe Ser Gly Ser Gly
Ser Gly Thr Asp Phe Thr 1 5 10 15 Leu Thr Ile Ser Ser Leu Gln Ala
Glu Asp Val Ala Val Tyr Tyr Cys 20 25 30 9811PRTMus sp. 98Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys Arg 1 5 10 9923PRTMus sp. 99Glu Ile
Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15
Glu Arg Ala Thr Leu Ser Cys 20 10015PRTMus sp. 100Trp Tyr Gln Gln
Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr 1 5 10 15 10132PRTMus
sp. 101Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe
Thr 1 5 10 15 Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val
Tyr Tyr Cys 20 25 30 10211PRTMus sp. 102Phe Gly Gly Gly Thr Lys Val
Glu Ile Lys Arg 1 5 10 10323PRTMus sp. 103Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr
Ile Thr Cys 20 10415PRTMus sp. 104Trp Tyr Gln Gln Lys Pro Glu Lys
Ala Pro Lys Ser Leu Ile Tyr 1 5 10 15 10532PRTMus sp. 105Gly Val
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 1 5 10 15
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 20
25 30 10611PRTMus sp. 106Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
Arg 1 5 10 10723PRTMus sp. 107Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys
20 10815PRTMus sp. 108Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile Tyr 1 5 10 15 10932PRTMus sp. 109Gly Val Pro Ser Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 1 5 10 15 Leu Thr Ile
Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 20 25 30
11011PRTMus sp. 110Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 1 5
10 111726DNAUnknownDescription of Unknown Unknown wild-type
polynucleotide 111gaggtccagc ttcagcagtc aggacctgac ctggtgaaac
ctggggcctc agtgaggata 60tcctgcaagg cttctggata cacattcact gactacaaca
tacactgggt gaaacagagc 120catggaaaga gccttgagtg gattggatat
atttatcctt acaatggtat tactggctac 180aaccagaaat tcaagagcaa
ggccacattg actgtagaca gttcctccaa tacagcctac 240atggacctcc
gcagcctgac atctgaggac tctgcagtct atttttgtgc tagagacgct
300tatgattacg actggttggc ttactggggc caagggactc tggtcactgt
ctctgcaggt 360cccgccaagg agttgacgcc cctgaaggag gcgaaggtct
ctgacatctt gctgactcag 420tctccagtca tcctgtctgt gagtccagga
gaaagagtca gtttctcctg cagggccagt 480cagagcattg gcacaaacat
atattggtat cagcaaagaa caaatggttc tccaaggctt 540ctcataaagt
atgcttctga gtctatctct gggatccctt ccaggtttag tggcagtggg
600tcagggacag attttactct tagcatcaac agtgtggagt ctgaagatat
tgctgattat 660tactgtcaac aaagtaataa ctggccatac acgttcggag
gggggaccaa gctggaaata 720aaacgg 726112726DNAUnknownDescription of
Unknown Unknown wild-type polynucleotide 112ctccaggtcg aagtcgtcag
tcctggactg gaccactttg gaccccggag tcactcctat 60aggacgttcc gaagacctat
gtgtaagtga ctgatgttgt atgtgaccca ctttgtctcg 120gtacctttct
cggaactcac ctaacctata taaataggaa tgttaccata atgaccgatg
180ttggtcttta agttctcgtt ccggtgtaac tgacatctgt caaggaggtt
atgtcggatg 240tacctggagg cgtcggactg tagactcctg agacgtcaga
taaaaacacg atctctgcga 300atactaatgc tgaccaaccg aatgaccccg
gttccctgag accagtgaca gagacgtcca 360gggcggttcc tcaactgcgg
ggacttcctc cgcttccaga gactgtagaa cgactgagtc 420agaggtcagt
aggacagaca ctcaggtcct ctttctcagt caaagaggac gtcccggtca
480gtctcgtaac cgtgtttgta tataaccata gtcgtttctt gtttaccaag
aggttccgaa 540gagtatttca tacgaagact cagatagaga ccctagggaa
ggtccaaatc accgtcaccc 600agtccctgtc taaaatgaga atcgtagttg
tcacacctca gacttctata acgactaata 660atgacagttg tttcattatt
gaccggtatg tgcaagcctc ccccctggtt cgacctttat 720tttgcc 726
* * * * *